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Resumo 
 
 
O objetivo principal deste trabalho foi a concepção de novos processos 
downstream para aplicações analíticas e biotecnológicas. Este trabalho foi 
dividido em três partes principais: formulação de novos SAB formados por 
polímeros, dependentes do uso inovador de líquidos iónicos como eletrólitos; 
design de sistemas aquosos bifásicos como uma alternativa para a extração 
da benzoilecgnonina e dois alucinógenos (harmina e harmalina); purificação 
por FPLC da L – Asparaginase I. Para cada capítulo, um resumo mais 
detalhado foi elaborado. Mostra-se que os bioprocessos de separação aqui 
estudados nomeadamente SAB e FPLC são alternativas viáveis às demais, 
devido aos altos rendimentos e maior seletividade obtidos. Para além disso, 
estes são relativamente simples e rápidos e de um ponto de vista operacional, 
apresentam baixo custo e são fáceis de escalonar. 
A partir dos estudos analíticos, concluiu-se que mais trabalhos são 
necessários para a aplicação de SABs como plataformas de extracção de 
drogas ilícitas, principalmente por causa da baixa concentração das mesmas 
em matrizes complexas, como a urina e Ayahuasca. Melhores resultados 
foram obtidos, quando se utilizou os SABs como plataformas de extracção de 
compostos biotecnológicos, em que foi possível maximizar o desempenho de 
extracção tanto do citocromo c como do ácido cloranílico, utilizando baixas 
concentrações de líquido iónico (0,1 % em massa), como eletrólitos. Também 
a purificação por FPLC da His-Tagg ASPase I recombinante foi efectuada com 
sucesso, obtendo uma recuperação de 81,03 ± 0,01 % e um fator de 
purificação 17 vezes relativamente à amostra original, proveniente do meio 
fermentativo. 
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Abstract 
 
The main objective of this work was the design of novel downstream processes 
for analytical and biotechnological applications. This work was divided in three 
major topics:   formulation of novel polymer-based ABS systems with innovative 
use of IL as electrolytes; design of aqueous biphasic systems as an alternative 
for extraction of benzoylecgnonine and two hallucinogens (harmine and 
harmaline); FPLC purification of L-Asparaginase I. For each chapter, a detailed 
summary is presented. The downstream processes herein studied namely ABS 
and FPLC are good alternatives, due to the high yields and enhanced 
selectivity obtained. Moreover, they are relatively simple and fast from the 
operational point of view, present a low cost and are easy to scale up.  
The analytical studies show that further work is required for the application of 
ABS as drug extracting platforms, mainly because of the very low concentration 
of drugs in complex matrixes, such as urine and Ayahuasca. Better results 
were obtained using ABS as biotechnological extracting platforms, being 
possible to maximize the extractive performance of Cyt c and CA, using low 
concentrations of IL (0.1 wt%) as electrolytes. Furthermore, the FPLC 
purification of His-Tagg recombinant ASPase I was successfully performed, 
obtaining a recovery of 81.03 ± 0.01 % and a purification factor of 17 times 
relatively to the original sample from fermentation broth. 
 
  
 
 
 
 
XIII 
 
Contents 
 
General Context .............................................................................................................. 1 
General objectives .......................................................................................................... 4 
Chapter I ............................................................................................................................. 5 
1.1. Introduction .................................................................................................................. 6 
1.2. Materials and methods ................................................................................................. 9 
1.2.1. Materials .................................................................................................................. 9 
1.2.2. Binodal curves determination ................................................................................ 10 
1.2.3. Partitioning studies of Cyt c, CA and ILs .............................................................. 11 
1.3. Results and discussion ................................................................................................ 13 
1.3.1. Design of polymeric ABS with ILs as electrolytes.................................................. 13 
1.3.1.1. Electrolytes’ impact on the ABS formation ..................................................... 13 
1.3.1.2. Characterization of ILs’ partition and media pH ............................................. 17 
1.3.2. Application of the studied ABS as purification platforms ..................................... 18 
1.4. Conclusions ................................................................................................................. 22 
1.5. Future work ................................................................................................................ 23 
Chapter II ......................................................................................................................... 25 
2.1. Introduction ............................................................................................................ 26 
2.1.1. Cocaine and benzoylecgnonine............................................................................. 27 
2.1.2. Harmine and harmaline ......................................................................................... 29 
2.2. Material and methods ............................................................................................ 31 
Phase diagrams of IL/K3PO4-based ABS ......................................................................... 31 
2.2.1. Materials ................................................................................................................. 31 
2.2.2. Experimental determination of phase diagrams ..................................................... 31 
Benzoylecgnonine ............................................................................................................ 32 
2.2.3. Materials ................................................................................................................. 32 
2.2.4. Benzoylecgonine extraction using IL/K3PO4-based ABS ...................................... 32 
2.2.5. HPLC quantification of benzoylecgnonine ............................................................ 32 
Harmine and harmaline .................................................................................................... 33 
2.2.6. Materials ................................................................................................................. 33 
2.2.7. Ayahuasca pre-treatment ........................................................................................ 34 
2.2.8. ABS extraction of hallucinogens from Ayahuasca ................................................ 34 
2.2.9. Capillary electrophoresis quantification of hallucinogens ..................................... 35 
2.3. Results and Discussion ........................................................................................... 36 
2.3.1. Analysis of the Phase Diagrams ........................................................................... 36 
2.3.2. Benzoylecgnonine extraction ................................................................................ 37 
2.3.3. Harmine and harmaline extraction ........................................................................ 39 
2.4. Conclusions and future work ................................................................................ 43 
XIV 
 
Chapter III ........................................................................................................................ 45 
3.1. State-of-art .................................................................................................................. 46 
3.2. Scopes ........................................................................................................................... 50 
3.3. Materials and Methods .............................................................................................. 51 
3.3.1. Protein Expression.................................................................................................. 51 
3.3.2. Cell lysis and sample pre-treatment ....................................................................... 52 
3.3.3. Ni2+- affinity chromatography ................................................................................ 52 
3.3.4. Nessler activity assay ............................................................................................. 53 
3.3.5. Protein quantification method ................................................................................ 54 
3.3.6. Polyacrylamide gel electrophoresis combined with silver staining ....................... 55 
3.4. Results and discussion ................................................................................................ 56 
3.5. Conclusions ................................................................................................................. 59 
3.6. Future work ................................................................................................................ 59 
General Conclusions .................................................................................................... 61 
References ......................................................................................................................... 63 
Acknowledgements ......................................................................................................... 71 
 
 
 
XV 
 
List of tables 
 
Table 1. General ranks of the electrolytes’ aptitude to promote ABS formation. 
 
Table 2.  FPLC purification with imidazole linear gradient (0 mM - 500 mM) at 5.0 
mL.min-1. Fractions eluted with ASNase I activity are shown, along with protein 
concentration, enzymatic activity and specific activity values. 
 
Table 3.  FPLC purification with two-step concentrations of the initial imidazole 
concentration (32.0 and 54.4 %) were applied.at 5.0 mL.min-1. Fractions eluted with 
ASNase I activity are shown, along with protein concentration, enzymatic activity, specific 
activity, purification factor and recovery parameters. 
 
  
XVII 
 
List of figures 
Figure  1. Chemical structure of CA (a) and horse heart Cyt c (b). 
 
Figure 2. Chemical structure and abbreviations of the ILs studied in this work. 
 
Figure 3. Binodal curves of the polymeric ABS containing 5 wt% of electrolyte (either 
inorganic salts or ILs): NaCl (), Na2SO4 (), [C2mim][N(CN)2] (), [C2mim][Tos]  (+), 
[C2mim][CF3SO3] (), [C2mim]Cl (), [Ch]Cl (), [OHC2mim]Cl (), 
[C2mim][CH3CO2] (), [N2,2,2,2]Br (), [C2mim][CH3SO3] (), [N2,2,2,2]Cl (), 
[C2mim][DMP] (). Binodal curves adjusted using Eq. 1 are represented in dashed lines. The influence of IL’s structural features is provided separately in the insets to simplify the 
analysis.  
 
Figure 4. Binodal curves of different types of ABS: PEG 8000 (component 1) + NaPA 
8000 (component 2) + [C2mim]Cl as electrolyte (), [C2mim]Cl (component 1) + K3PO4 
(component 2) (),  PEG 1500 (component 1) + K3PO4 (component 2) + [C2mim]Cl as 
adjuvant (▲)38, PEG 1500 (component 1) + [C2mim]Cl (component 2) ()35. 
 
Figure 5. Binodal curves of polymeric ABS at different electrolytes’ concentration: 5 wt% 
of NaCl (▲), 2.5 wt% of NaCl (), 0.1 wt% NaCl (), 5 wt% of [C2mim][N(CN)2] (), 
2.5 wt% of [C2mim][N(CN)2] () and 0.1 wt % [C2mim][N(CN)2] (). Binodal curves 
adjusted using Eq.1 are represented in dashed lines. The arrow is a guide to the eye. 
 
Figure 6. KIL (blue bars) of [C2mim]-based ILs and pH values of the corresponding 
bottom-phase of the systems (). The lines are provided just to guide the eye.  
 
Figure 7. Extraction efficiencies (EE, %) for CA (purple bars) and Cyt c (pink bars) in the 
ABS composed of 15.0 wt% of PEG + 4.5 wt% of NaPA + 5.0 wt% of electrolytes 
(inorganic salts or [C2mim][X]). The colour of the phases allows a visual inspection of the 
migration preferences. 
 
Figure 8. Effect of [C2mim][N(CN)2] concentration on the partition coefficients, KCA (blue 
bars) and percentage extraction efficiency data, EECA, % () of CA. 
 
Figure 9. Cocaine and its primary metabolites, including benzoylecgonine (BE)64. 
Figure 10. Ayahuasca  sample. 
 
Figure 11. Filtration paper with fine particles retained (pore size of 0.45 ȝm).  
 
Figure 12. Centrifuged extract with brown solid contaminant pellets.   
 
Figure 13. (a) Capillary electrophoresis equipment P/ACE 5050 system (Beckman) (b) 
Detailed view of microtubes containing Ayahuasca  samples. 
 
Figure 14. Binodal curves of the IL/K3PO4-based ABS composed of [C2mim]Cl (), 
[C2mim][CH3CO2] (), [N2,2,2,2]Br (), [C2mim][DMP] (), [C2mim][N(CN)2] (),  
XVIII 
 
[C2mim][Tos] (+), [C2mim][CF3SO3] () + K3PO4 at (298 ± 1) K. Binodal curves 
adjusted using Eq.5 are represented in dashed lines. The influence of IL’s structural 
features is provided separately in the insets to simplify the analysis. 
 
Figure 15. Liquid chromatogram of benzoylecgonine standard (100 ppm). 
 
Figure 16. HPLC chromatogram of the benzoylecgonine standard (black line), of the IL-
rich phase of blank human urine-based ABS (blue line) and of the IL-rich phase of drug-
containing human urine-based ABS (violet line). 
 
Figure 17. HPLC chromatogram of the benzoylecgonine standard (black line), of the salt-
rich phase of blank human urine-based ABS (blue line) and of the salt-rich phase of drug-
containing human urine-based ABS (violet line). 
 
Figure 18. Electropherogram of harmine and harmaline (100 ppm). Conditions: MEKC 
buffer containing 20 mM sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 % (v/v) 
methanol. Capillary 20 cm to the detector and 50 ȝm i.d., Applied current: 70 ȝA, 
hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1) K,  at a wavelength of 
336 nm. 
 
Figure 19. (a) [C2mim]Cl/K3PO4-based ABS extraction of hallucinogens from Ayahuasca 
pre-treated sample, in which [C2mim]Cl and K3PO4 are the top and bottom phase 
respectively.  (b) PEG 8000/NaPA 8000-based ABS extraction of hallucinogens from 
Ayahuasca pre-treated sample, in which PEG and NaPA are the top and bottom phase 
respectively. 
 
 
Figure 20. Electropherogram of IL-rich phase of [C2mim]Cl/K3PO4-based ABS prepared 
using the Ayahuasca  pre-treated sample. Conditions: MEKC buffer containing 20 mM 
sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 %(v/v) methanol. Capillary 20 cm to 
the detector and 50ȝm  i.d. , Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 
seconds, T = (293.1 ± 0.1)K,  wavelength 336 nm. 
 
Figure 21. Electropherogram of salt-rich phase of [C2mim]Cl/K3PO4-based ABS prepared 
using the Ayahuasca  pre-treated sample. Conditions: MEKC buffer containing 20 mM 
sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 %(v/v) methanol. Capillary 20 cm to 
the detector and 50ȝm  i.d. , Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 
seconds, T = (293.1 ± 0.1)K,  wavelength 336 nm. 
 
Figure 22. Electropherogram of PEG 8000-rich phase of PEG 8000/NaPA 8000-based 
ABS with [C2mim]Cl as electrolyte prepared using the Ayahuasca  pre-treated sample. 
Conditions: MEKC buffer containing 20 mM sodium tetraborate, TBS (pH 9.40), 40 mM 
SDS, 10 %(v/v) methanol. Capillary 20 cm to the detector and 50ȝm  i.d. , Applied current: 
70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1)K,  wavelength 
336 nm. 
 
Figure 23. Electropherogram of NaPA 8000-rich phase of PEG 8000/NaPA 8000-based 
ABS with [C2mim]Cl as electrolyte prepared using the Ayahuasca  pre-treated sample. 
XIX 
 
Conditions: MEKC buffer containing 20 mM sodium tetraborate, TBS (pH 9.40), 40 mM 
SDS, 10 %(v/v) methanol. Capillary 20 cm to the detector and 50ȝm i.d. , Applied current: 
70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1)K,  wavelength 
336 nm. 
 
 
Figure 24. Overview of normal human hematopoiesis109. Blood or Hematopoietic stem 
cells (HSCs) give rise to the myeloid (monocytes and macrophages, neutrophils, basophils, 
eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells), and lymphoid 
lineages (T-cells, B-cells, NK-cells). 
 
Figure 25. Schematic representation of the crystal L-asparaginase, resolution of 1.82 Å. 
(Extracted from Protein Data Bank, PDB code 2HIM). 
 
Figure 26. (a) FPLC™ (System ÄKTApurifier) formed by Pump P-900, Monitor UV-900, 
Monitor UPC-900, Valve INV-907, Mixer M-925 and Valves SV-903, FV-923 (b) 
HiTrapTM 5 mL IMAC FF column 
 
Figure 27. Linear gradient of imidazole used in FPLC purification, obtained from FPLC 
software. The blue line corresponds to absorbance at 280 nm. The black boxes (fractions 
14-18 and 20-31) 
 
Figure 28. Polyacrylamide gel electrophoresis combined with silver staining, showing the 
purified samples from linear step FPLC purification. The black boxes highlight the wash-
out unbound proteins (second lane) and histidine-tagged ASNase I bands (~ 45.0 KDa). In 
the different lanes are represented the eluted fractions and PM refers to Protein Markers. 
 
Figure 29. Polyacrylamide gel electrophoresis combined with silver staining, showing the 
purified samples from two-step FPLC purification. The brown box highlights the his-
tagged ASNase I bands (~ 45.0 KDa). In the different lanes are represented the eluted 
fractions and PM refers to Protein Markers. 
 
 
 
 
 
  
XXI 
 
List of Symbols  
 
EA – Enzymatic activity (in IU.mL-1) 
EECA – Extraction efficiency of chloranilic acid (in %) 
EECyt c - Extraction efficiency of cytochrome c (in %) 
i.d. – Internal diameter (in ȝm) 
KCA - Partition coefficient of chloranilic acid  
KIL - Partition coefficient of ionic liquid 
PF – Purification factor 
RT – Retention time (in min) 
SA – Specific enzymatic activity (in IU.mg-1) 
T – Temperature (in K) 
 
 
  
 
  
XXIII 
 
List of abbreviations  
ABS – Aqueous biphasic system 
ALL - Acute lymphoblastic leukemia 
ASNase – L-Asparaginase 
Asn - Asparagine 
ASP1 – Asparaginase I (gene) 
BE – Benzoylecgonine 
CA – Chloranic acid 
Cyt c – Cytochrome c 
CE – Capillary electrophoresis 
FPLC - Fast Protein Liquid Chromatography 
IL(s) – Ionic liquid(s) 
IU – International unit of enzyme activity 
MEKC - Micellar Electrokinetic Chromatography 
[C2mim]Cl - 1-ethyl-3-methylimidazolium chloride 
[C2mim][DMP] - 1-ethyl-3-methylimidazolium dimethylphosphate 
[C2mim][CH3SO3] - 1-ethyl-3-methylimidazolium methanesulfonate 
[C2mim][Tos] - 1-ethyl-3-methylimidazolium tosylate 
[C2mim][CH3CO2] - 1-ethyl-3-methylimidazolium acetate 
[C2mim][CF3SO3] - 1-ethyl-3-methylimidazolium triflate 
[C2mim][N(CN)2] - 1-ethyl-3-methylimidazolium dicyanamide 
[OHC2mim]Cl - 1-(2-hydroxyethyl)-3-methylimidazolium chloride 
[N2,2,2,2]Cl - tetraethylammonium chloride 
[N2,2,2,2]Br - tetraethylammonium bromide 
[C14mim]Cl - 1-tetradecyl-3-methylimidazolium chloride 
[Ch]Cl - choline chloride 
NaCl - Sodium chloride 
Na2SO4 - Sodium sulphate 
 
 
 
  
                                                              
 
 
General Context 
 
 
 
1 
 
General Context 
 
Biological compounds are important for many applications including bio-
transformations, diagnostics, research and development, food processes, pharmaceutical 
products, and toxicological studies. Depending of their usage, biological products can be 
obtained from crude extracts, fermentation broth, industrial wastes or biological raw 
materials (micro and macroalgae), with any previous purification and consequently 
exhibiting high contaminant content. For toxicological analysis, these products, that may or 
may not be biological (e.g. synthetic drugs) are required to be extracted from complex 
matrixes (e.g. hair, urine or blood). Nevertheless, some bioproducts, such as 
biopharmaceuticals typically require exceptional purity, making downstream processing 
the critical step of the overall process1. The downstream stage in industrial biotechnology 
refers to recovery, purification and isolation, of the microbial products from cell debris, 
processing medium and contaminant biomolecules from the upstream process into a 
finished product such as enzymes, dyes and proteins1,2. The downstream process design 
has the greatest impact on the overall bio-manufacturing costs because, not only does the 
biochemistry of different products (e.g., peptides, proteins, hormones, antibiotics, and 
complex antigens) dictate different methods for the isolation and purification of these 
products but also, the contaminating by-products can reduce the overall process yield, and 
may have serious consequences on clinical safety and efficacy. Therefore, downstream 
separation scientists and engineers are continually seeking to eliminate or combine unit 
operations to minimize the number of process steps, in order to maximize the product 
recovery at a specified concentration and more important, with a specific and very high 
purity level3,4.  
The downstream processes are continuously facing diverse challenges, namely 
considering the Biological products which are often present in very low concentration (e.g. 
monoclonal antibodies concentration of 0.1 mg.mL-1 in the mammalian cell culture 
supernatants). Therefore, in many cases, large volumes of dilute product streams have to be 
processed. For toxicological analysis, the toxins/drugs concentration is in an even lower 
concentration (in the order ng.mL-1); many impurities and by-products are present in the 
source material and they have chemical and physical properties similar to those of the 
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target product, which makes separation processes extremely challenging. Hence, 
bioseparation has to combine high yields and high selective to insure the product stability; 
there are stringent quality requirements for products used for pharmaceutical, diagnostic 
and therapeutic purposes, both in terms of active product content as well as in terms of the 
absence of specific impurities (e.g. injectable therapeutic products should be free from 
endotoxins and pyrogens). The design of these downstream processes is more problematic, 
due to the demanding purification requirements. Generally there is a need of a higher 
number of purification steps, reflected in a higher cost of overall downstream process; 
Biological products are susceptible to denaturation and other forms of degradation. 
Therefore bioseparation techniques have to be "gentle" in terms of avoiding extremes of 
physicochemical conditions such as pH and ionic strengths, hydrodynamic conditions such 
as high shear rates, and exposure to gas-liquid interfaces. Organic solvents which are 
widely used in chemical separations have relatively limited usage in bioseparations on 
account of their tendency to promote degradation of many biological products; many 
biological products are thermolabile and hence many bioseparation techniques are usually 
carried out at sub-ambient temperatures; bioseparation is frequently based on multi-
technique separation, where different downstream processes are interlinked in order to 
have an enhanced purification4–7. A widely recognized heuristic, also known as RIPP 
(Recovery, Isolation, Purification and Polishing) is commonly used in bioseparation8. This 
scheme categorizes downstream processing operations dividing them into four groups, 
which are applied in order to bring a product from its source as a component of a tissue, 
cell or fermentation broth, through progressive improvements in purity and concentration: 
1. Clarification or removal of non-soluble is the first step and it involves the capture 
of the product as a solute in a particulate-free liquid, for example the separation of cells, 
cell debris or other particulate matter from fermentation broth containing an antibiotic. 
Typical operations to achieve this are filtration, centrifugation, sedimentation, 
precipitation, flocculation, electro-precipitation, and gravity settling. Additional operations 
such as grinding, homogenization, or leaching are required to recover products from solid 
sources, such as plant and animal tissues, are also usually included in this group9. 
2. Product isolation is the removal of those components whose properties vary 
markedly from that of the desired product. For most products, water is the chief impurity 
and isolation steps are designed to remove most of it, reducing the volume of material to be 
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handled and concentrating the product. Solvent extraction, adsorption, ultrafiltration, and 
precipitation are some of the unit operations involved4,6. 
3. Product purification is done to separate those contaminants that resemble the 
product very closely in physical and chemical properties. Consequently, steps in this stage 
are expensive to carry out and require sensitive and sophisticated equipment. This stage 
contributes to a significant fraction of the entire downstream processing expenditure. 
Examples of operations include affinity, size exclusion, reversed phase chromatography2, 
crystallization4, fractional precipitation8 or liquid-liquid extraction10. 
4. Product polishing describes the final processing steps which end with packaging 
of the product in a form that is stable, easily transportable and convenient. Crystallization, 
desiccation, lyophilisation and spray drying are typical unit operations7. Depending on the 
product and its intended use, polishing may also include operations to sterilize the product 
and remove or deactivate trace contaminants which might compromise product safety. 
Such operations might include the removal of viruses or depyrogenation. 
The high-throughput, low-resolution techniques are first used to significantly reduce 
the volume and overall concentration of the material being processed. In the other hand, 
the partially purified products are then further processed by high-resolution low-throughput 
techniques to obtain pure and polished finished products3,8. 
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General objectives 
 
In this work we pretended to design novel extraction techniques to be applied as 
downstream processes based in FPLC and ABS methodologies.  
It is our intention to create new polymer-based ABS, with the innovative addition of 
ionic liquids as electrolytes to overcome the limited range of polarities of the phase 
polymers and consequently promote the phase separation. Moreover, the influence of 
several parameters on the ABS formation, namely the ILs’ presence, structural features (in 
particular IL family and anion conjugated) and concentration were study. We intend to find 
the smallest IL concentration that exhibit high extraction efficiency. Extraction studies 
with probe molecules, in particular, chloranilic acid and cytochrome c were accomplish in 
order to discern the yield and extraction efficiency of these systems as extraction platforms 
(Chapter I).  
Then, and after the proper design of these polymeric ABS, it is proposed the design 
of aqueous biphasic systems as an alternative for extraction of benzoylecgnonine and two 
hallucinogen compounds, namely harmine and harmaline from complex matrixes, 
respectively human urine and Ayahuasca. The analytical method was based on two stages: 
the first consists on the sample pre-concentration using ionic liquids-based aqueous 
biphasic systems (namely ILs as electrolyte and IL/salt systems); the second involves the 
quantification of the target compounds by HPLC for benzoylecgonine and capillary 
electrophoresis for both hallucinogens (Chapter II). 
Finally it was intended to purify L-ASNase I with a low number of purifying steps, 
obtaining a pure enzyme with high yields and specific activity, using FPLC downstream 
process, in order to be scaled-up for a promissory commercial pharmaceutical application. 
The FPLC purification was performed in two different stages. In the first stage a linear 
gradient, running from 0 mM to 500 mM of imidazole at 5.0 mL.min-1 was perform in 
order to identify the lowest imidazole concentration of the elution buffer that extracts the 
higher amount of L-ASNase I. In the second stage, two-step gradient of imidazole was 
performed for an optimized L-ASNase I purification. Polyacrylamide gel electrophoresis 
combined with silver staining and Nessler activity assay were also used in order to confirm 
the presence of the purified L-Asparaginase I (Chapter III).  
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Chapter I  
 
 
Ionic liquids as a novel class of electrolytes 
in polymeric aqueous biphasic systems 
 
 
Abstract 
The design of a novel eco-friendly and cheap aqueous biphasic systems composed of two 
polymers, namely poly(ethylene glycol) of average molecular weight 8000 g.mol-1 and 
sodium poly(acrylate) of molecular weight 8000 g.mol-1 (here designed by PEG 8000 and 
NaPA 8000) using ionic liquids (ILs) as electrolytes and their application in 
(bio)separation processes are here attempted. The binodal curves were established at (298 
± 1) K and atmospheric pressure, considering distinct ILs and inorganic salts. These 
systems enabled the assessment of the influence of several parameters on the ABS 
formation, namely the ILs’ presence, structural features (in particular IL family and anion 
conjugated) and concentration. In general, ILs revealed the capability to act as electrolytes, 
promoting the phase separation. Moreover, the resulting ABS were characterized in terms 
of the ILs partitioning behaviour, which preferentially occurred towards the NaPA 8000-
rich phase, and the media pH. The capacity of these ABS in terms of extraction 
technologies was tested taking into account the goal of carrying out partition experiments 
for two distinct molecules, namely the protein cytochrome c (Cyt c) and the probe dye 
chloranilic acid (CA). The results suggest that they displayed opposite migrations: Cyt c 
was totally recovered in the NaPA 8000-rich phase (EECyt c > 96.13 ± 3.22 % when ILs are 
present acting as electrolytes), while CA is selectively migrating towards the PEG 8000-
rich phase (EECA > 80.13 ± 1.45 % for IL as electrolytes). The decrease of the IL 
concentration on the polymer-based ABS leads to a significant increase in the partition 
coefficient of CA (KCA) towards the PEG 8000-rich phase, suggesting that the use of low 
amounts of IL (0.1 wt%, for example) is an advantageous condition to boost the extractive 
performance of different bio(molecules) including Cyt c and CA. 
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1.1. Introduction    
Aqueous biphasic systems (ABS) were originally proposed by Albertsson11 as 
cleaner liquid-liquid extraction processes that could be used as potential substitutes for the 
conventional ones. This is mainly due to the fact that ABS are not derived from hazardous 
and volatile organic solvents and present abundant water contents12, providing milder and 
more biocompatible conditions for bioseparation/downstream processes. In fact, ABS are 
able to maintain the native conformation and biological activity of diverse biomolecules, 
while exhibiting high yields and purity levels. Evidences of their successful application are 
well-documented for a wide array of compounds, namely proteins8,13–15, enzymes16,17, 
cells18,19 and antibiotics20–22. Apart from their environmentally benign status, ABS are full 
of flexibility related with the countless types of chemical compounds that can be combined 
to create them, e.g. polymer + polymer15,17,23,24, polymer + salt20,25,26 or salt + salt27–30. 
Polyethylene glycol (PEG) is a non-ionic polymer commonly used in the ABS 
domain, since it presents advantageous characteristics in terms of biodegradability, toxicity 
and cost-effectiveness. In order to create polymeric ABS, blends of PEG with other 
polymers, such as maltodextrin23,24 and specially dextran13,31, are within the most common 
options. However, these are expensive and display high viscosities and opacities as well as 
limited range of polarities of the phases. Moreover, although the number of polymers is 
huge, some of the potential polymer pairs are not able to form ABS, limiting the variety of 
systems. This scenario triggered the creation of novel lines of research focused on the 
search for improved ABS capable of overcoming such drawbacks.  
One of the proposed strategies regards the minimization of the polymers’ amounts, 
i.e. increasing those of water. This can be attained through the complementary addition of 
small amounts of salts (e.g. 1.05 to 6 wt%)32 acting as electrolytes and allowing the phase 
split. In systems without salt addition the two-phase formation only occurs at very high 
polymer concentrations, and therefore, the presence of these salts is mandatory for the 
ABS formation. For instance, NaCl (sodium chloride), Na2SO4 (sodium suflate), NaOOC-
(CH2)7-COONa (di-sodium azelate) and NaOOC-(CH2)4-COONa (di-sodium adipate) have 
been successfully applied as electrolytes in polymeric ABS composed of PEG-sodium 
polyacrylate (NaPA)32 and PEG-poly(acrylic) acid (PA)33,34. At the end, properly selecting 
the electrolyte structure, it was possible to increase the biphasic region32, making possible 
to work at very low polymer concentrations (e.g. 10 wt% of each polymer). Indeed, these 
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systems have been widely applied to the extraction of proteins, namely, hemoglobin15, 
lysozyme15, glucose-6-phospate dehydrogenase (G6PDH)15 and green fluorescent protein 
(GFP)14. Since such systems were shown to maintain the native conformation and 
biological activity of biomolecules, associated with high yields of purification14,15, they are 
believed to be more biocompatible routes. Another approach passed for the substitution of 
one of the polymers by a high melting temperature salt which benefits from somehow 
lower viscosities and opacities of the whole ABS. More recently, the use of ionic liquids 
(ILs) as either main phase forming agents35–37 or adjuvants38–40 (addition of small amounts 
of ILs, at circa  5 wt%) emerged. Remarkably, the introduction of such ionic compounds in 
polymeric ABS significantly enlarges the polarity differences between the phases35,40. ILs 
are salts in the liquid state below a stated temperature of 100 ºC, conventionally composed 
of a large organic cation and an anion of either inorganic or organic nature28. They present 
unique characteristics such as, the insignificant vapour pressure and flammability, being 
these the main reasons why ILs are labelled as greener solvents. Moreover, they possess 
high chemical and thermal stabilities28 and outstanding capability of solvating compounds 
from a wide spectrum of polarities35,41. These characteristics have contributed for the 
recognition of ILs as fascinating phase forming agents in ABS. Furthermore, the ILs’ 
status of designer solvents42, i.e. (almost) immeasurable cation/anion possible 
combinations, brings the possibility to manipulate ABS phases’ polarities and to develop 
systems with affinities for certain tailored application.  
In this work, ILs were applied as electrolytes in the domain of polymeric ABS. The 
experimental phase diagrams of ABS based on polyethylene glycol (PEG) and sodium 
polyacrylate (NaPA), both with the same molecular weight of 8000 g.mol-1, were 
established at (298 ± 1) K and atmospheric pressure. The choice of these polymers was 
supported by their simple recycling that enables their application at larger scale32. Different 
imidazolium and ammonium-based ILs and two high melting temperature salts, NaCl and 
Na2SO4, were applied as electrolytes. These allowed the comparative assessment between 
the performance of ILs and inorganic salts as electrolytes in polymeric ABS. Testing out 
the designer solvent status, it was possible to investigate the impact of several structural 
modifications at the level of the cation core and the anion moiety on the binodal curves 
behaviour. Moreover, these novel ABS were characterized in terms of electrolyte 
(imidazolium-based ILs) partition between the phases and pH of the aqueous medium. The 
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ABS here developed were then applied in the extraction of two different molecules, the 
Cytochrome c (Cyt c) and Chloranilic acid (CA), herein used as model compounds. Cyt c 
is an electron-carrying mitochondrial heme protein (red colour) containing a single 
polypeptide chain and a single heme group, which is covalently attached to cysteine 
residues, namely: Cys-14 and Cys-17. The ready fluctuation of Cyt c within the cell 
between the ferrous and ferric states makes it an efficient biological electron-transporter, 
which plays a vital role in cellular oxidations in both plants and animals. It is generally 
regarded as a universal catalyst of respiration, forming an essential electron-bridge 
between the respirable substrates and oxygen43. CA is a small organic dye presenting red-
brown colour in dry conditions or violet in aqueous medium35. The main field of 
application of CA is in the analytical chemistry, for spectrophotometric determinations 
(e.g. determination of three macrolides i.e., erythromycin, roxithromycin and 
clarithromycin through charge transfer complexes44). These molecules were considered as 
probe molecules, due to their very distinct chemical structure and complexity, and their 
activity. The extractive performance of these systems was investigated by using the 
imidazolium-based ILs at distinct concentrations, and the inorganic salts (for comparative 
analysis).   
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1.2. Materials and methods 
1.2.1. Materials 
PEG 8000 and the aqueous solution of NaPA 8000 (45 wt%) were purchased at 
Sigma-Aldrich® and were used as received. The salts NaSO4 and NaCl were acquired at 
Synth®. The two molecules CA (purity > 99 wt%) and Cyt c from equine heart (purity = 95 
wt%) were purchased at Merck® and Sigma-Aldrich®, respectively. Their chemical 
structures are provided in Figure 1. Eleven distinct ILs were used: 1-ethyl-3-
methylimidazolium chloride [C2mim]Cl (purity > 98 wt%), 1-ethyl-3-methylimidazolium 
dimethylphosphate [C2mim][DMP] (purity > 98 wt%), 1-ethyl-3-methylimidazolium 
methanesulfonate [C2mim][CH3SO3] (purity > 99 wt%), 1-ethyl-3-methylimidazolium 
tosylate [C2mim][Tos] (purity = 99 wt%), 1-ethyl-3-methylimidazolium acetate 
[C2mim][CH3CO2] (purity > 95 wt%), 1-ethyl-3-methylimidazolium triflate 
[C2mim][CF3SO3] (purity = 99 wt%), 1-ethyl-3-methylimidazolium dicyanamide 
[C2mim][N(CN)2] (purity > 98 wt%), 1-(2-hydroxyethyl)-3-methylimidazolium chloride 
[OHC2mim] Cl (purity = 99 wt%), tetraethylammonium chloride [N2,2,2,2]Cl (purity > 
98%), tetraethylammonium bromide [N2,2,2,2]Br (purity > 98 wt%)   and choline chloride 
[Ch]Cl (purity > 98 wt%). The imidazolium based-ILs were acquired at Iolitec® (Ionic 
Liquid Technologies, Germany). [N2,2,2,2]Cl and [Ch]Cl were acquired from Sigma-
Aldrich®, while [N2,2,2,2]Br was purchased at Fluka AG – Chemische. The [C14mim]Cl 
studies are presented in 1.5. Future work section. The chemical structures of all ILs are 
depicted in Figure 2. The water used was double distilled, passed by a reverse osmosis 
system and further treated with a Milli-Q plus 185 water purification apparatus. 
 
 
 
 
 
 
 
(b) (a) 
Figure  1. Chemical structure of CA (a) and horse heart Cyt c (b). 
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Figure 2. Chemical structure and abbreviations of the ILs studied in this work. 
 
1.2.2. Binodal curves determination 
The experimental binodal curves were determined using the cloud point titration 
method at (298 ± 1) K and atmospheric pressure, following a protocol previously described 
in literature45. Briefly, three stock aqueous solutions were prepared: 50 wt% of PEG 8000 
+ 5 wt% of IL or inorganic salt, 40 wt% of NaPA 8000 + 5 wt% of IL or inorganic salt and 
water + 5 wt% of IL or inorganic salt. Additionally, the IL/inorganic salt concentration was 
varied from 5 wt% to 2.5 wt% and 0.1 wt%, aiming to assess its effect on the behaviour of 
 
 
 
 
[C2mim]Cl [C2mim][DMP] [C2mim][CH3SO3] 
 
 
 
 
 
 
[C2mim][Tos] [C2mim][CH3CO2] [C2mim][CF3SO3] 
 
 
 
[C2mim][N(CN)2] [OHC2mim]Cl [N2,2,2,2]Cl 
   
[N2,2,2,2]Br [Ch]Cl  
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the binodal data. Drop-wise addition of a PEG 8000-containing solution was performed to 
a solution of NaPA 8000 until the visual detection of two phases. Subsequently, drop-wise 
addition of the IL/inorganic salt-containing solution was conducted until the two phases 
disappear (monophasic region). This procedure was repeated several times to obtain the 
binodal curve, being performed under constant stirring, within an uncertainty of ± 10-4 g. 
The experimental phase diagrams data were correlated using the Merchuk equation46 (1), 
described as follows:                                                            (1) 
where [PEG 8000] and [NaPA 8000] represent the weight percentages of PEG 8000 and 
NaPA 8000, respectively and A, B and C are constants obtained by the regression of the 
experimental data. The Merchuk equation was chosen since it has a low number of 
adjustable parameters to correlate these data and it is the most commonly used30. 
  
1.2.3. Partitioning studies of Cyt c, CA and ILs  
A mixture point within the biphasic region was selected and prepared by weighing 
the appropriate amounts of each compound: 15 wt% of PEG 8000 + 4.5 wt% of NaPA 
8000 + 5 wt% of electrolyte + 0.1 g of a Cyt c stock solution (at circa 5.0 g.L-1) or 1 g of a 
CA stock solution (at circa 0.72 g.L-1) for 5 g of total mass. For the partitioning studies of 
the target molecules, only the imidazolium-based ILs and the inorganic salts were used. To 
investigate the effect of electrolyte concentration, systems containing [C2mim][N(CN)2] 
and NaCl were selected to carry out partitioning studies of CA. The same mixture 
compositions aforementioned were prepared, varying only the amount of electrolyte from 5 
wt% to 2.5 wt% and 0.1 wt%. All the components were mixed together using a Vortex 
agitator (IKA, C-MAG HS7), and then equilibrated at (298 ± 1) K and atmospheric 
pressure during 12 h, allowing the equilibrium to be reached. At the end, the final systems 
resulted in two clear phases, a PEG 8000-rich as the top and a NaPA 8000-rich as the 
bottom layer, with a well-defined interface in between. The coexisting phases were then 
carefully separated and collected for the measurement of their volumes, weights and pH 
values as well as for the quantification assays. 
The determination of the target compounds and imidazolium-based ILs content was 
assessed using a Molecular Devices Spectramax 384 Plus | UV-Vis Microplate Reader, at 
the respective maximum wavelength of absorbance, namely 409 nm for Cyt c, 330 nm for 
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CA, and 211 nm for all ILs (except the choline and ammonium structures). At least three 
independent samples of each system were prepared, being the average values reported 
along with the respective standard deviations.  
 The IL partition coefficient (KIL) was calculated as the ratio between the amount of 
IL present in the bottom and top phases, as described by Eq. 2:                                            (2)      
where Abs(ILB) and Abs(ILT) are the IL absorbance output measured for the bottom and 
top phases, respectively. 
The CA partition coefficient (KCA) is defined by the ratio of the CA concentration in 
the top phase, [CA]T, to that in bottom the phase, [CA]B – Eq. 3.                                                      (3) 
The percentage extraction efficiency (EE, %) was calculated for both biomolecules 
following Eq. 4:                                                                         (4)  
where Vi and [M]i are the initial volume and the initial concentration of molecule added to 
prepare the extraction systems, while Vmolecule-rich and [M]molecule-rich denote the volume and 
concentration of dye in the phase where it is more concentrated: top phase in the case of 
CA (EECA) and bottom phase for Cyt c (EECyt c). It should be noted that blank controls 
where the CA or the Cyt c solutions were replaced by water were constantly applied to 
remove possible interferences from the phase components. 
The pH values of both phases were measured at (298 ± 1) K using a Digimed DM-22 
dual meter pH equipment with an uncertainty ± 0.02. 
 
 
 
 
 
 
 
 
 
  
 
                                                              Ionic liquids as a novel class of electrolytes in polymeric aqueous biphasic systems  
 
13 
 
1.3. Results and discussion 
1.3.1. Design of polymeric ABS with ILs as electrolytes 
1.3.1.1. Electrolytes’ impact on the ABS formation 
 
Although Johansson et al.32 have addressed the influence of inorganic salts as 
electrolytes in phase diagrams of ABS composed of PEG 2000, 4000 and 8000 and NaPA 
8000, this is the first time that ILs have been used as electrolytes. The experimental 
binodal curves here determined and the respective adjustments by the Merchuk equation 
are provided in Figs. 3, 4 and 5 in molality units (mole of solute per kg of solvent), while 
the detailed experimental weight fraction data, respective correlations (adjusted parameters 
A, B and C) and binodal curves in mass fraction units are represented in Table A.1-6 and 
Fig. A.2-3 from Appendix A. The ILs employed allow the investigation of several 
parameters related with the application of ILs as electrolytes, namely the anion moiety, the 
cation core and their concentration. Table 1 reports all trends gauged for the electrolytes’ 
aptitude to promote phase separation, organized according to each parameter evaluated. 
The principal results demonstrate that, as for inorganic salts, NaCl and Na2SO4, ILs 
of different families are also capable to induce the formation of ABS (Fig. 3). Despite the 
higher capability of to induce the phase separation demonstrated by the inorganic salts, 
probably due to the higher charge density, it seems that the manipulation of the phase split 
can be achieved by adding distinct ILs by playing with the combination cation/anion (Fig. 
3 and Table 1). However, it should be mentioned that these systems have in general higher 
capacity to induce the phase separation, when compared with other IL-containing ABS 
(e.g. IL + polymer, polymer + inorganic salt + IL as adjuvant, IL + salt)28, as can be seen in 
Fig. 4, in Fig. B.3 from Appendix B the phase diagram is provided in mass fraction units. 
This is of major importance, since there is a natural interest to find out systems that can 
move the binodal curve closer to the water rich region in the phase diagram, due to the low 
component content (polymer/salt) required, reducing the overall cost and viscosity and 
increasing the biocompatibility of the ABS.  
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Table 1. General ranks of the electrolytes’ aptitude to promote ABS formation. 
 
Parameters Rank of the electrolytes’ performance  
Salts vs. ILs NaCl ≈ Na2SO4 > ILs 
IL anion moiety 
[C2mim]-based ILs:  
[N(CN)2]- > [Tos]- ≈ [CF3SO3]- > Cl- > [CH3CO2]- > [CH3SO3]-  > [DMP]- 
 
[N2,2,2,2]-based ILs: 
Br- > Cl- 
IL cation core Cl
-
-based ILs: 
[Ch]+ ≈ [C2mim]+ > [OHC2mim]+ > [N2,2,2,2]+  
Electrolyte  
Concentration 
NaCl:  
5 wt% ≈ 2.5 wt% >> 0.1 wt% 
 
[C2mim][N(CN)2]: 
5 wt% > 2.5 wt% >> 0.1 wt% 
 
 
 
 
Figure 3. Binodal curves of the polymeric ABS containing 5 wt% of electrolyte (either inorganic salts or 
ILs): NaCl (), Na2SO4 (), [C2mim][N(CN)2] (), [C2mim][Tos]  (+), [C2mim][CF3SO3] (), [C2mim]Cl 
(), [Ch]Cl (), [OHC2mim]Cl (), [C2mim][CH3CO2] (), [N2,2,2,2]Br (), [C2mim][CH3SO3] (), 
[N2,2,2,2]Cl (), [C2mim][DMP] (). Binodal curves adjusted using Eq. 1 are represented in dashed lines. The influence of IL’s structural features is provided separately in the insets to simplify the analysis. 
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Figure 4. Binodal curves of different types of ABS: PEG 8000 (component 1) + NaPA 8000 (component 2) 
+ [C2mim]Cl as electrolyte (), [C2mim]Cl (component 1) + K3PO4 (component 2) (),  PEG 1500 
(component 1) + K3PO4 (component 2) + [C2mim]Cl as adjuvant (▲)38, PEG 1500 (component 1) + 
[C2mim]Cl (component 2) ()35. 
 
 
The impact of several anion moieties on the polymeric ABS formation was assessed 
by using either [C2mim]-based or [N2,2,2,2]-based ILs and their binodal data are sketched in 
Fig. 3. Eight distinct anions, namely Cl-, Br-, [DMP]-, [CH3SO3]-, [Tos]-, [CH3CO2]-, 
[CF3SO3]- and [N(CN)2]- were investigated, and their aptitude to promote the phase 
separation is given in Table 1. The trends here gauged are similar to those highlighted in 
previous works for ABS composed of imidazolium-45 and ammonium-based47 ILs and 
salts. It has been shown that the enhanced ability to undergo phase separation is closely 
related to the decrease on the hydrogen-bond basicity (β)28,48 depending on the anion. In 
fact, ILs sharing the [C4mim]+ cation combined with anions such as [CH3CO2]-, [CH3SO3]- 
and halogens (Cl- and Br-) have higher β, presenting a shorter biphasic region, while those 
paired with [CF3SO3]- and [N(CN)2]- present lower β, possessing thus, a higher ability to 
two-phase formation45,48. Moreover, for ILs sharing the [C2mim]+ cation the same trend is 
verified, where anions such as, triflate [CF3SO3]- present higher aptitude to form ABS than 
their  halogens (Cl-) based counterparts45. 
The cation core effect on the aptitude to induce the ABS formation was evaluated 
using ILs with a common Cl- anion conjugated with four distinct cations, those differing 
from being either aromatic or aliphatic: [C2mim]+, [OHC2mim]+, [N2,2,2,2]+ and [Ch]+. The 
  
 
                                                              Ionic liquids as a novel class of electrolytes in polymeric aqueous biphasic systems  
 
16 
 
binodal curves are depicted in Fig. 3 and the general ability to perform ABS is reported on 
Table 1. There seems to be two different driving forces influencing the ABS behaviour: for 
the imidazolium-based ILs the increasing hydrophobicity from [C2mimOH]+ to [C2mim]+ 
of the cation core moves the binodal curve towards the water-rich region, as well-reported 
in literature28,35; for the ammonium-based compounds ([N2,2,2,2]Cl and [Ch]Cl), a reversed 
effect is noticed. In this case, [N2,2,2,2]+ represents the most hydrophobic core being 
however the less able to promote the separation of the phases (contrarily to the well-
described trends that indicate that ammonium-based compounds are more efficient at 
creating ABS than their imidazolium counterparts27,29). This indicates that other parameters 
beyond the hydrophobic nature of the cation are influencing the ABS formation. 
Meanwhile, most works assessing the impact of the cation core are related with IL/salts-
based ABS; when dealing with polymeric ABS containing ILs, the interactions are by far 
more intricate, and consequently, additional molecular insights are needed. 
The effect of electrolyte concentration on the ABS formation was studied by varying 
the amount of either NaCl and [C2mim][N(CN)2] (IL with the highest capacity to promote 
ABS formation) from 5 wt% to 2.5 wt% and down to 0.1 wt%. The binodal curves 
determined are depicted in Fig. 5. By increasing the electrolyte concentration (increasing 
the ionic strength) enhanced capacities to perform ABS are accomplished (Table 1). For 
higher concentrations of NaCl, the effect is narrower, becoming more significant when its 
amount is reduced; on the other hand, a more pronounced effect is observed for the IL. 
Such tendency is in agreement with the results reported by Johansson et al.32 for polymeric 
ABS using inorganic salts as electrolytes; however concentrations below 1.05 wt% have 
never been studied. Moreover, in polymer/salt-based ABS containing ILs as adjuvants, the 
increasing amount of IL enhanced the aptitude to ABS formation, as verified here39. 
Remarkably, the stronger aptitude of NaCl to undergo phase separation compared to 
[C2mim][N(CN)2] can be minimized at lower electrolyte concentrations (e.g. 0.1 wt%) 
opening new perspectives on the use of ILs as electrolytes in polymeric ABS.  
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Figure 5. Binodal curves of polymeric ABS at different electrolytes’ concentration: 5 wt% of NaCl (▲), 2.5 
wt% of NaCl (), 0.1 wt% NaCl (), 5 wt% of [C2mim][N(CN)2] (), 2.5 wt% of [C2mim][N(CN)2] () 
and 0.1 wt % [C2mim][N(CN)2] (). Binodal curves adjusted using Eq. 1 are represented in dashed lines. 
The arrow is a guide to the eye. 
    
1.3.1.2. Characterization of ILs’ partition and media pH  
After the determination of the binodal curves which allow the selection of 
appropriate mixtures at the biphasic region (thus, performing ABS), the understanding of 
ILs’ partition (KIL) as well as the pH of the systems are of utmost importance for the final 
application, i.e. to be used as extraction/purification processes. This was investigated by 
using the [C2mim]-based ILs which display maximum absorbance at 211 nm.  
In Fig. 6 the KIL along with the pH values of the systems are reported. By the 
analysis of pH variation with the ILs used as electrolytes, only minor variations from 7 to 8 
were observed. Although these systems are not buffered, the pH is kept constant at neutral 
values, allowing the maintenance of the molecules’ charge as constant during the partition 
experiments. The ILs’ partitioning behavior, given by the KIL (Eq. 2), follows the trend 
[C2mim][DMP] ≈ [OHC2mim]Cl > [C2mim][CH3SO3] > [C2mim][CF3SO3] > 
[C2mim][CH3CO2] > [C2mim][Tos] > [C2mim]Cl > [C2mim][N(CN)2]. It is clear that the 
IL migrates towards the NaPA-rich phase (KIL > 1), with the exception of 
[C2mim][N(CN)2], which is equally distributed among both aqueous phases (KIL = 1). This 
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preferential migration is easily justified by the electrostatic interactions between the ILs’ 
cation core with the negatively charged species of the polymer – NaPA is negatively 
charged at neutral pH, due to the presence of carboxylic groups in the main chain. For the 
specific case of [C2mim][N(CN)2], its stronger hydrophobic nature may instigate  
additional interactions that start to deviate the IL’s migration towards the PEG-rich phase. 
Also in PEG/salt-based ABS using ILs as adjuvants, the nature of the IL dictated the 
partitioning phenomenon towards either the PEG-rich or the salt-rich phase39,40.       
 
 
 
 
 
 
 
 
Figure 6. KIL (blue bars) of [C2mim]-based ILs and pH values of the corresponding bottom-phase of the 
systems (). The lines are provided just to guide the eye.  
 
 
1.3.2. Application of the studied ABS as purification platforms  
In order to provide the proof of applicability of this novel class of ABS as 
purification platforms, partitioning studies of two probe molecules, namely CA and Cyt c, 
were conducted. Those were carried out using ABS composed of 15 wt% PEG 8000 + 4.5 
wt% NaPA 8000 + 5 wt% of electrolyte (either ILs or inorganic salts). Due to practical 
limitations related to the analytical detection of Cyt c content in the bottom phase, it was 
not possible to determine the KCyt c. Thereby, the comparison of the partitioning 
phenomenon of the target molecules was performed taking into account the EE values.   
The EE data attained for CA and Cyt c using the polymeric ABS herein developed 
are provided in Fig. 7. In fact, high EE values were attained ranging from 80.13 ± 1.45 % 
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to 97.85 ± 1.37 % for CA for top phase and from 86.23 ± 3.75 % to 100 % for Cyt c for 
bottom phase. From these results, it is possible to observe the total migration of Cyt c and 
CA towards opposite directions in all the systems investigated, which demonstrates their 
selective extraction. For these two compounds, the selectivity is not a crucial point, 
however, these results suggest that it will be possible to manipulate the selective extraction 
of similar compounds through, the proper design of the ABS applied. Meanwhile, it is 
noticed that the protein (a much more complex chemical structure) partitions towards the 
NaPA 8000-rich phase (bottom phase), while the CA is more concentrated in the PEG 
8000-rich phase (top phase). This scenario can be explained based on the balance of 
interactions and effects occurring between the main components of the aqueous system, 
which are related with the intrinsic properties of each ABS phase and those of the target 
molecules (the dissociation curves of the target compounds and the pH values of the 
coexisting phases of each ABS are provided in Fig. A.1-2 from Appendix A). The partition 
phenomenon of Cyt c is governed by “NaPA 8000 – Cyt c” interactions, since Cyt c is 
positively charged at pH at around 7 (pI ≈ 10.0)43, giving rise to electrostatic interactions 
with the charged species of the NaPA 8000. It should be stressed that the presence of 
electrolytes in NaPA 8000-rich phase (“Cyt c-electrolyte” additional interactions) is likely 
incrementing the strength of such interactions. Conversely, the preferential migration of 
CA towards the PEG 8000-rich phase seems to be controlled by a balance between, “PEG 
8000-CA” interactions and, specially, “NaPA 8000-CA” repulsive effects. If in one hand, 
CA displays a logP of 1.22 that indicates a slightly higher preference towards hydrophobic 
environments (e.g. PEG 8000 layer), on the other hand, this dye is negatively charged at 
neutral pH (pKa of 0.58 and 3.18)35, being intensely expelled from NaPA-rich phase. 
Meanwhile, no significant differences with the electrolyte adopted at the level of the 
extractive performances are observed. Additionally, the KCA values determined for this set 
of ABS along with additional pictures of each coloured/uncoloured phases (for CA and Cyt 
c) are provided in Fig.A.4 and Table A.7 from Appendix A, aimed at merely supporting 
the migration preference observed. In general, the KCA, contrarily to the EECA, is boosted 
by the use of inorganic salts (maximum KCA of 10.91 ± 0.41 attained for Na2SO4) as 
electrolytes when compared to ILs (maximum KCA of 4.18 ± 0.29 obtained for 
[C2mim][DMP]). 
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Figure 7. Extraction efficiencies (EE, %) for CA (purple bars) and Cyt c (pink bars) in the ABS composed of 15.0 wt% of PEG + 4.5 wt% of NaPA + 5.0 wt% of 
electrolytes (inorganic salts or [C2mim][X]). The colour of the phases allows a visual inspection of the migration preferences.  
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As an attempt to improve the extractive performance of the ABS using ILs as 
electrolytes, the amount of IL was minimized, ranging from 5 wt%, 2.5 wt% to 0.1 wt%. 
ABS containing [C2mim][N(CN)2] as electrolyte were selected due to the lowest KCA 
attained (Table A.7 from Appendix A) and availability of the binodal curves at different IL 
concentration (see section 1.3.1.1. of Results and Discussion). The results obtained for both 
KCA and EECA values are shown in Fig. 8, which clearly indicate that the lowest IL 
concentration (0.1 wt%) is prompting the CA migration towards the PEG 8000-rich phase 
(circa 5 times more than with the use of 5 wt% of IL). These results indicate that, beyond 
the “PEG 8000-CA” interactions and the “NaPA 8000-CA” repulsive effects, also “CA-
ILs” interactions between the aromatic rings of CA and [C2mim][N(CN)2] (ππ stacking) 
may occur. At lower IL concentrations, “CA-ILs” interactions are much weaker and thus, 
the repulsive effect of NaPA 8000 upon the dye towards the PEG 8000-rich phase is even 
stronger, boosting the KCA values. Remarkably, this minimization of IL content causes a 
significant enhancement at the level of KCA up to 12.44 ± 1.08, which is equivalent or even 
larger than those obtained with 5 wt% of inorganic salts (10.91 ± 0.41 for Na2SO4 and 5.27 
± 0.51 for NaCl). It should be noted that although the trend of the extractive performance 
with the [C2mim][N(CN)2] concentration is scattered, evidences of improvements at lower 
concentrations are noticed as the EECA increases at circa  10 – 15 % (Fig. 8). From this set 
of results emerges the idea that lowering the amounts of IL employed as electrolyte, not 
only the extractive performance, but also the economic and environmental aspects of this 
class of ABS are improved, encouraging more studies to optimize their behaviour at the 
molecular level and extraction performance. In fact, these systems can be used in a near 
future to extract and purify molecules from marine raw materials, by taking advantages of 
the higher amounts need to promote the ABS formation, by using the water constituting the 
marine raw materials. 
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Figure 8. Effect of [C2mim][N(CN)2] concentration on the partition coefficients, KCA (blue bars) and 
extraction efficiency data, EECA, % () of CA. 
 
 
1.4. Conclusions 
In this work, new experimental phase diagrams composed of PEG 8000 + NaPA 
8000 + water and several ILs as electrolytes were determined at (298 ± 1) K and 
atmospheric pressure. Firstly, it is important to remark that this class of ABS reveals great 
aptitude to undergo phase separation when compared to other classes. The ability of the 
electrolytes to promote the ABS formation is ruled by the electrolytes’ ionic strength, 
being the inorganic salts (NaCl and Na2SO4) more effective than the ILs here investigated. 
It should be noted that this discrepancy fades at lower concentrations of electrolyte. 
Considering the IL structural features, the anion moiety effect is well-defined, i.e. lower 
hydrogen-bond basicities induce larger biphasic regions; however, the effect of the cation 
core is more intricate. When the concentration of electrolyte is taken into account, higher 
amounts are more beneficial to the ABS formation. In a mixture belonging to the biphasic 
region of each binodal curve, these systems result in a PEG 8000-rich (top) phase and a 
NaPA 8000-rich (bottom) phase, for which the IL migrates. The application of these ABS 
in the extraction of Cyt c and CA revealed an efficient selective process. In other words, 
Cyt c completely migrated towards the NaPA 8000-rich phase, mainly due to electrostatic 
interactions, whereas CA was totally expelled towards the PEG 8000-rich phase as a result 
  
 
                                                              Ionic liquids as a novel class of electrolytes in polymeric aqueous biphasic systems  
 
23 
 
of repulsive effects. Within the set of parameters optimized (electrolyte type and 
concentration, as well as IL structural features), it was possible to significantly improve the 
extraction parameters by simply lowering the IL concentration down to 0.1 wt%. In this 
context, both cost and environmental impacts allied with ILs employed as electrolytes are 
significantly reduced, instigating the creation of more competitive and attractive 
technologies. 
 
1.5. Future work 
A more extensive screening, with other IL families should be accomplished, as an 
attempt to identify ILs’ structures with higher ability of promoting the ABS formation and 
their actuation mechanism. In this context, two main strategies should be adopted; the first 
regards the use ILs of more benign nature, namely belonging to the cholinium family while 
the second considers the application of ILs with tensioactive properties, due to their high 
hydrophobicity and ability to form micelles. Additionally, the application of these types of 
ABS should be applied in the extraction of added-value compounds from real matrices, 
such as fermentation media or marine raw materials.  
 Aiming at providing further insights into the interactions controlling the partition 
phenomenon, further partition studies with other molecules should be carried out. Also, in 
order to understand the mechanisms governing the phase separation, molecular-level 
studies should be performed, e.g. using NMR, COSMO-RS as well as molecular dynamics 
simulation. Moreover, the investigation of other polymer blends should be carried in the 
future, not only to validate the applicability of ILs as electrolytes, but also to find more 
advantageous/effective systems.  
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Chapter II  
 
Application of ABS as analytical tools in the 
forensic toxicology field 
  
Abstract 
The present work describes two alternative methods to detect benzoylecgonine (cocaine 
main metabolite) in human urine samples and harmine and harmaline in Ayahuasca 
preparations (Santo Daime). The method was based on two stages: the first consists on the 
sample pre-concentration using ionic liquids-based aqueous biphasic systems (IL-based 
ABS); the second involves the quantification of the target compounds by HPLC for 
benzoylecgonine and capillary electrophoresis for two hallucinogens. Both methods were 
shown to be easy and fast from a practical perspective. However, the data gauged suggest 
that in both cases, the ABS were not successful in the pre-concentration stage, indicating 
the need for further studies. 
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2.1. Introduction 
Toxicology is a multidisciplinary science that studies the adverse effects of 
chemicals on living organisms49. One of its most emerging areas is forensic toxicology, 
which can be defined as the science that works with biological fluid proofs, diagnosing 
exogenous intoxications, normally related with criminal practices49,50. Currently, forensic 
toxicology is an area in constant change, as new poisons and drugs are daily discovered 
many of them from the new human lifestyle. Forensic toxicology has been facing constant 
technological challenges: if in one hand, the new technologies available in analytical 
chemistry allow more accurate quantification/detection/identification, on the other hand, 
the constant appearance of novel drugs hampers the creation of standard protocols50. The 
major drawbacks in the forensic field are firstly related with the sample preparation as the 
sample amount available for analysis is frequently extremely low, the matrices usually 
present high degrees of complexity and the target compounds are commonly present in 
trace levels. Moreover, it is likely that the limit of detection (LOD) of the quantification 
techniques is higher than the amounts of target analyte present in the sample, precluding its 
quantification. Bearing this in mind, there is an urgent need for more powerful pre-
concentration approaches. The sample preparation is currently performed using 
conventional liquid-liquid extraction (LLE), solid phase extraction (SPE) and purge-and-
trap; however, novel extractive approaches such as micro-sample preparation techniques 
and aqueous biphasic systems based on ionic liquids (IL-based ABS) are being proposed as 
more advantageous alternatives51,52. Despite of the differences between them, such 
techniques are simple and fast from an operational perspective and require low or even null 
amounts of volatile solvents.  
The first report on IL-based ABS was given by Rogers and co-workers53 that proved 
that hydrophilic IL in contact with aqueous solution of a phosphate-based salt can create 
two aqueous phases, which can be in separation processes, among other possible 
applications. Since then, several works have been applying distinct ILs, expanding the 
cation/anion possible combinations to be used, and different salts beyond the phosphate-
based ones, as recently reviewed by Freire et al.28. In fact, the designer solvent status42 
given to ILs is relevant in the design of extractive/analytical approaches for a molecule of 
interest. The applications for IL-based ABS are nowadays vast and versatile ranging from 
the recovery of drugs from pharmaceutical wastes47 to the extraction of natural colorants54 
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and lipolytic enzymes16,55 from fermentation broths. In analytical chemistry, this class of 
ABS was successfully applied as sample pre-treatment techniques for doping agents56 and 
endocrine disruptors57 from urine or opium alkaloids from Pericarpium papaveris58. For 
instance, it is reported that is possible “to concentrate bisphenol A up to 100-fold in one 
single step procedure using IL-based ABS”57. Moreover, the abundant content in water, the 
non-usage of hazardous organic solvents and the low cost of the experimental apparatus12 
make this an attractive technique for the preparation of sample for forensic purposes. 
In this work, IL-based ABS are proposed as alternative routes for sample preparation 
in what concerns the detection of alkaloids of forensic interest. For that, the first step was 
the establishment of the experimental ternary phase diagrams for 1-ethyl-3-
methylimidazolium ([C2mim])-based ILs + potassium phosphate tribasic (K3PO4) + water 
systems at (298 ± 1) K and atmospheric pressure. After that, partitioning studies of the 
alkaloids were conducted using the systems determined with two distinct purposes: the first 
regards the extraction of cocaine from human urine for further quantification using high 
performance liquid chromatography (HPLC); the second intends to recover hallucinogens 
present in tea to be quantified using a novel analytical method based on capillary 
electrophoresis (CE). In the following sections of the introduction (see sections 2.1.1 and 
2.1.2) it is provided more detailed information about the alkaloids used in this 
investigation. 
 
2.1.1. Cocaine and benzoylecgnonine 
 Cocaine, formally known as benzoylmethylecgonine, is the major alkaloid obtained 
from the leaves of coca plant (Erythroxylum coca). This psychotropic drug has a long 
history of human use and abuse. It is a stimulant, appetite suppressant and nonspecific 
voltage gated sodium channel blocker that causes anaesthesia at low doses59,60. Cocaine 
can be introduced into the body by intranasal ("snorting") or intravenous (injecting) entries, 
oral ingestion, or smoking the free base form (commonly referred to as "crack")61,62. 
According to United Nations World Drug Report (New York, 2013), the global area under 
coca cultivation amounted to 155,600 ha in 2011. The amounts of cocaine manufactured 
(expressed in quantities of pure cocaine) were estimated to range from 776 to 1,051 tons in 
2011. The world’s largest cocaine seizures were reported to take place in Colombia (200 
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tons) and in the USA (94 tons). The cocaine market seems to be expanding, which leads to 
massive concerning levels of consumption worldwide. 
Cocaine displays several metabolites (Fig. 9); for instance, in 1990 Zhang et al.63 
have found 11 metabolites, including four never reported before. The major metabolites of 
cocaine are easily recognizable and detectable. The degradation of cocaine into its 
metabolites is a result either from hydrolysis or oxidation biochemical reactions. Cocaine 
(A) in Figure 9 is oxidized by specific cytochromes P450 (CYPs) and N-demethylated to 
into norcocaine (B). It can be further oxidized into N-hydroxy cocaine (C), a low probable 
metabolite, by oxidative metabolism. Benzoylecgonine (D) and ecgonine methyl ester (E) 
are formed from the ester cleavage hydrolytic reaction of cocaine by serum cholinesterases 
and hepatic carboxylesterases. Further hydrolysis of these compounds leads to the 
formation of ecgonine (F), another major metabolite59,60. 
 
Figure. 9 Cocaine and its primary metabolites, including benzoylecgonine (BE)64. 
 
Around 86-90% of an administered dose of cocaine is recovered in urine as either 
cocaine (only 1-5 %) or one of its metabolites. Among the degradation metabolites, 
benzoylecgonine is the one provided of major toxicological and analytical importance. 
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This is mainly due to the fact that it presents longer half-live than cocaine65 and consists of 
46% of the excreted metabolites59. However, its content in urine is in the order of ng.mL-1 
units, which represents a limiting step for the accurate quantification of this metabolite. 
Recently, many studies have been carried out with the aim of improving drug 
detection present in samples of human origin, such as hair66–69, urine64,70–75 and 
blood69,73,74,76,77. This is highly important for a comprehensive set of applications, namely 
drug abuse studies, analysis in forensic toxicology, drug use monitoring in workplace and 
doping control in competitions. Several research works have been dealing with the 
development of analytical methods for drug detection in samples from human origin. Most 
of these studies use solid-phase extraction (SPE)67,68,75,78 as sample preparation method. 
Meanwhile, the detection or quantification of cocaine and/or respective metabolites present 
in diverse samples is mainly conducted by using gas chromatography coupled with mass 
spectrometry (GC–MS)66,72,74 and high performance liquid chromatography (HPLC) with 
UV detection 71,75. However, for GC-MS analysis the sample must be derivatizated, what 
introduces an additional cost to the method. Moreover, both SPE and GC–MS are time-
consuming techniques, which use higher volumes of hazardous chemicals (e.g. organic 
solvents) and require a lot of sample manipulation. Additionally, few studies on SPME 
application in benzoylecgonine extraction from urine72 and hair66 appeared. 
 
2.1.2. Harmine and harmaline 
Ayahuasca, also known by the names Hoasca, Daime, Yajé, Natema and Vegetal, is 
a psychoactive tea plant originally used by shamans in the Amazon Basin in magical-
religious practices and folk medicine of indigenous people79,80. This beverage is obtained 
by infusing the powdered stems of Banisteriopsis caapi in combination with the leaves of 
Psychotria viridis. Psychotria viridis contains the psychedelic agent called N,N-
dimethyltryptamine (DMT), whereas B. caapi contains β-carbolines such as harmine, 
harmaline and tetrahydroharmine, which are potent monoamine oxidase (MAO) inhibitors. 
Dimethyltryptamine is not orally active itself, since it is inactivated by peripheral MAO 
present in liver and gut. However, the inhibition of MAO by β-carbolines allows the oral 
activity of dimethyltryptamine, enabling its action towards the central nervous system. The 
synergistic interaction of these alkaloids is the basis of the psychotropic action of 
Ayahuasca81. In Brazil, Ayahuasca has been incorporated in rituals of modern syncretic 
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religious groups, mainly the Santo Daime and the União do Vegetal (UDV), where the 
beverage is reported to be used to facilitate self-knowledge and introspection. In 2004, the 
use of Ayahuasca within religious context was officially recognised and protected by law 
in Brazil (Conselho Nacional Antidrogas Brasil, 2004). Up to date, Brazil is the only 
country where it is held under legal protection, analogous to the status of peyote 
(Lophophora williamsii) usage in the United States82. The use of Ayahuasca has spread 
outside South America, being now established in the United States and in Europe 80. With 
the increasing consumption of such psychotropic tea, this beverage has begun to attract the 
attention of researchers in what regards its pharmacological and toxicological aspects79–84. 
In the last years, several authors have devoted their attention in the characterization 
of the Ayahuasca alkaloids’ profile. The peruvian Ayahuasca (100 mL) was shown to 
contain dimethyltryptamine (60 mg), harmine (467 mg), harmaline (41 mg) and 
tetrahydroharmine (160 mg), being this characterization achieved through two-dimensional 
thin-layer chromatography, HPLC and GC-MS84. On its turn, the composition of Brazilian 
Ayahuasca (100 mL) has been shown to comprise 24, 170, 20 and 107 mg of the same 
alkaloids, respectively, using GC and HPLC85.  
Among the vast number of analytical techniques that can be used in the forensic 
toxicology field, capillary electrophoresis (CE) arises as one of the most important tools in 
the screening and quantification of illicit drugs, bio-transformed products and other 
forensic medicines. In fact, a huge number of articles regarding the CE application in the 
quantification of several drugs can be found in literature37-45. In the last years, the widely 
applied separation and quantification techniques HPLC and GC-MS, has been looked with 
minor interest, largely because of the lack of applicability in forensic toxicology. It is when 
CE gains considerable attention, due to the higher separation power (up to millions of 
theoretical dishes), rapid analysis time, high mass sensitivity and low cost associated 
(small sample volumes required and consumables)69,86. This technique is also provided of 
considerable flexibility from both separation mode (e.g. electrophoretic, electrokinetic 
chromatography) and detection (e.g. UV-visible, fluorescence, conductivity, mass) points 
of view86–94. Micellar electrokinetic chromatography (MEKC) was adopted during this 
work for the quantification of harmine and harmaline extracted from tea with IL-based 
ABS. This technique is based on a mobile phase (buffer) containing a surfactant, 
commonly sodium dodecyl sulfate (SDS). The presence of a surfactant induces the creation 
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of micelles, allowing the analytes to be distributed between the hydrophobic interior of the 
micelle and the hydrophilic buffer solution. To enable the quantification of these 
hallucinogens aroused the need for the development and validation of a new analytical 
method.  
 
2.2. Material and methods 
Phase diagrams of IL/K3PO4-based ABS 
2.2.1. Materials 
The  ILs used in this chapter of the present thesis were [C2mim]Cl, [C2mim][DMP],  
[C2mim][CH3SO3], [C2mim][Tos], [C2mim][CH3CO2], [C2mim][CF3SO3], 
[C2mim][N(CN)2] and [N2,2,2,2]Br. Their suppliers, purities, full name and chemical 
structures are reported on Chapter 1, Section 1.2.1. The salt potassium phosphate tribasic 
K3PO4 (97 wt%) was purchased from Sigma-Aldrich®. The water used was double 
distilled, passed by a reverse osmosis system and further treated with a Milli-Q plus 185 
water purification apparatus. 
2.2.2. Experimental determination of phase diagrams 
In order to complete the series of ABS studied in the present work, the experimental 
ternary phase diagrams for the systems composed of several [C2mim]-based ([C2mim]Cl, 
[C2mim][DMP], [C2mim][Tos], [C2mim][CH3CO2], [C2mim][CF3SO3], [C2mim][N(CN)2]) 
and [N2,2,2,2]-based ([N2,2,2,2]Br) ILs + K3PO4 (pH ≈ 13) + water were determined at (298 ± 
1) K and atmospheric pressure. The cloud point titration method was elected in order to 
determine the experimental binodal curves, following a general experimental procedure 
already established in previous works45. Aqueous stock solutions at ca. 80 wt% of each IL 
and at ca. 50 wt% K3PO4 (pH ≈ 13) were prepared. Drop-wise addition of the aqueous 
solution of K3PO4 was performed to the IL aqueous solution until the visual perception of a 
cloudy point (biphasic region). Alternate drop-wise addition of water until the appearance 
of a clear solution (monophasic region) was then conducted. The experimental solubility 
curves were correlated using the Merchuk equation46:                                              (5)  
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where [IL] and [K3PO4] represent, respectively, the IL and K3PO4 mass fraction 
percentages, and A, B and C are the constants obtained by the regression of the 
experimental binodal data. 
 
Benzoylecgnonine 
2.2.3. Materials 
Benzoylecgonine (Fig. 9) free base standard, 1 mg.mL-1 in methanol, was obtained 
from Sigma-Aldrich®. Urine samples from human origin were collected from a non-drug 
consumer and stored at -20ºC, until they were processed for further extraction and 
quantification. HPLC grade methanol was acquired at Merck® and ammonium acetate 
(purity = 99 %) was retrieved from Sigma-Aldrich®. 
 
2.2.4. Benzoylecgonine extraction using IL/K3PO4-based ABS 
ABS of 5 g of total weight were prepared gravimetrically using glass vials by 
adding 40 wt% of [N2,2,2,2]Br (herein adopted as model IL) + 15 wt% of K3PO4 + 45 wt% 
of human urine samples spiked with 100 ȝL of the solution of benzoylecgonine in 
methanol (to obtain a final concentration of 2 ppm of benzoylecgonine in the total ABS 
volume). At the end, the selected mixtures were able to undergo two phases separation, in 
with a top phase richer in [N2,2,2,2]Br and a bottom phase richer in K3PO4. At this time, the 
phases were carefully separated and collected for the measurement of their weight 
(uncertainty of ±10-4 g), volume and pH. The pH of both IL-rich and salt-rich phases was 
measured using a Mettler Toledo S47 SevenMultiTM dual meter pH/conductivity 
equipment with an uncertainty of ±0.02. 
 
2.2.5. HPLC quantification of benzoylecgnonine 
The quantification of benzoylecgnonine was assayed by HPLC analysis. A liquid 
chromatograph consisted of an automatic sampler, pump and diode array detector (DAD). 
The analytical column adopted was Luna® 5 µm C18 100 Å with dimensions of 250 x 4.6 
mm (Phenomenex). The procedure adopted was that previously reported by Clauwaert et 
al.75, in which the separation was carried out by gradient elution. The mobile phase was 
composed of 0.045 M ammonium acetate buffer solution (pH 6.5) and methanol. The 
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phase components were degassed prior to use. The program of elution was conducted 
according to 0 – 30 min from 10 to 60 % of methanol, 30 – 32 min from 60 to 10 % of 
methanol and 32 – 40 min 10 % of methanol. The operation flow-rate was 1 mL.min-1 and 
the injection volume was 10 ȝL. DAD detector was set to record the UV spectra and to 
measure the column eluent at 241 nm. The identity of benzoylecgnonine was assessed 
through a comparison of the retention time (24.3 min) and UV spectra obtained for urine 
(benzoylecgnonine at a concentration of 2 ppm in total ABS volume) to those attained for 
standard samples (benzoylecgnonine at a concentration of 100 ppm).   
 
Harmine and harmaline 
2.2.6. Materials  
 The pure standards of the alkaloids harmaline hydrochloride dihydrate (purity = 
95%) and harmine (purity = 98%) - chemical structures are in Fig. B.1 from Appendix B - 
were both purchased from Sigma-Aldrich®. The alkaloid powders were dissolved in 
methanol (analytical-reagent grade) at a concentration of 1 mg.mL-1 and stored at 4 ºC 
under light-protected conditions. Ayahuasca preparations were obtained from a 
religious group settled in the city of Araçoiaba da Serra, State of São Paulo, Brazil (Fig. 
10). 
 For capillary electrophoresis, the MEKC buffer consisted in sodium tetraborate 
(TBS) from Synth® and sodium dodecyl sulphate (SDS) acquired from Sigma-Aldrich®. 
Methanol was obtained from Sigma-Aldrich® with high purity grades. 
 
Figure 10. Ayahuasca  sample. 
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2.2.7. Ayahuasca pre-treatment  
 Ayahuasca was diluted with Milli-Q water (1:2) and posteriorly centrifuged at 
16000 x g for 10 minutes at room temperature. The resulting pellet was discarded, being 
then the supernatant filtered under vacuum using membrane filters (pore size of 0.45 ȝm) 
(Fig. 11 and 12). The aqueous supernatant obtained was further used in the ABS extraction 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.8. ABS extraction of hallucinogens from Ayahuasca 
Two types of ABS were performed to extract harmaline and harmine from 
Ayahuasca supernatant solution: [C2mim]Cl/K3PO4-based ABS and PEG 8000/NaPA 
8000-based ABS with [C2mim]Cl as electrolyte. The [C2mim]Cl/K3PO4-based ABS were 
prepared gravimetrically using glass vials by adding 40 wt% of [C2mim]Cl + 15 wt% of 
K3PO4 + 45 wt% of Ayahuasca  aqueous supernatant completing a total weight of 5 g. 
These systems result in two phases, being the IL-rich and the salt-rich phases represented 
as the top and the bottom layers, respectively. In its turn, polymeric ABS (for further 
details see Chapter 1) were composed of 15 wt% of PEG 8000 + 4.5 wt% of NaPA 8000 + 
5.0 wt% of [C2mim]Cl + 75.5 wt% of Ayahuasca  aqueous supernatant fulfilling a total 
weight of 5 g. Two phases clearly occur, being the PEG 8000 more concentrated in the top 
phase, while NaPA 8000 mostly appears in the bottom phase. The phases of both types of 
ABS were carefully separated and collected for the measurement of their weight 
Figure 12. Centrifuged extract with brown solid 
contaminant pellets.   
Figure 11. Filtration paper with fine particles 
retained (pore size of 0.45 ȝm). 
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(uncertainty of ± 10-4 g), volume and pH. The pH was assessed using a Mettler Toledo S47 
SevenMultiTM dual meter pH/conductivity equipment with an uncertainty of ± 0.02. 
 
2.2.9. Capillary electrophoresis quantification of hallucinogens  
 MEKC buffer was freshly prepared and consisted of 20 mM of TBS (pH 9.40), 40 
mM of SDS, containing 10% (v/v) methanol. It should be stressed out that an optimization 
study was performed, being other conditions tested, as described along the text. The 
buffers were filtered (0.4 ȝm filters) and kept at 4 ºC prior to be used.  
MEKC was performed on the P/ACE 5050 system (Beckman) (Fig. 13) in the 
normal-polarity mode (positive potential at the injection end of the capillary). The 
temperature was set at 298 (± 1) K and UV absorbance was monitored at 336 nm using 
DAD (Beckman Instruments, CA, USA). Peak identity was confirmed by post-run DAD 
analysis of the maximum absorption of the individual peaks in a mixture of both standards. 
An unmodified fused-silica capillary (J&W Scientific) was used for all analysis. The 
capillary has the following dimensions 20 cm effective length   50 ȝm internal diameter. 
Prior to analysis, it was conditioned with 5 volumes of NaOH, 10 volumes of Milli-Q 
water and 20 volumes of MEKC buffer and it was then subjected to voltage equilibration 
for 10 minutes until the accomplishment of a stable baseline. Samples’ introduction was 
performed by pressurised injection (0.5 psi, 30 s). Separations were conducted under 
constant electric current (70 ȝA, 15 minutes). Between analysis, the capillary was washed 
for 10 minutes with NaOH, 10 minutes with Milli-Q water and then 15 minutes with the 
MEKC buffer.  
 
 
 
 
 
 
 
 
 
Figure 13. (a) Capillary electrophoresis equipment P/ACE 5050 system (Beckman) (b) Detailed view of 
microtubes containing the Ayahuasca  samples. 
(a) (b) 
  
 
                                                                 Application of ABS as analytical tools in the forensic toxicology field 
  
 
36 
 
2.3. Results and Discussion 
2.3.1. Analysis of the Phase Diagrams  
Ventura et al.45 reported the phase behaviour of ternary systems composed of 
[C2mim]-based ILs + K3PO4 + H2O. Herein, a complementary study was carried out aimed 
at incrementing the series of anions ([Tos]-, Cl-, [DMP]-, [CH3CO2]-, [CF3SO3]-and 
[N(CN)2]-) and cations ([N2,2,2,2]+) available for this strong salting-out agent (stronger 
salting-out agents are more prone to promote the re-concentration of diverse analytes57). 
The experimental binodal curves adjusted by the Merchuk equation were plotted in Fig. 14 
in units of molality (mole of solute per kg of solvent) to eliminate possible interferences 
caused by the discrepancies on the ILs’ molecular weight on the binodal curves behaviour. 
The detailed experimental weight fraction data, respective correlations (adjusted 
parameters A, B and C) and phase diagrams in mass fraction units are represented in Table 
B.1-3 and Fig. B.2-3 from Appendix B. The binodal curves established allowed the 
comparison among the effect of different anion moieties (with ILs sharing either the 
[C2mim]+ or the [N2,2,2,2]+ cations). 
In what regards the anion effect on the ABS formation, their ability to induce phase 
separation can be ranked as follows: 
[C2mim]-based ILs: [CF3SO3]- ≈ [Tos]- > [N(CN)2]- ≈ [DMP]- > [CH3CO2]- ≈ Cl-  
These results are in good agreement with the whole set of evidences found in 
literature for the IL’s anion effect on the ABS formation45,47,95. This is typically correlated 
based on the capability to create water-ions hydration complexes, which depends on the β 
of the anions. In other words, anions with lower β values display lower abilities to form 
coordinative bonds and therefore are more easily salted-out by K3PO4, which is translated 
into extended biphasic regions. As aforementioned, the trend for the anions performance 
when ILs are working as electrolytes in polymeric ABS (see Chapter 1) is also in good 
agreement with such findings.  
Concerning the cation core impact on the creation of ABS, it is possible to 
generally conclude that the system containing the quaternary ammonium [N2,2,2,2]+ is more 
prone to undergo phase separation than the one composed of [C2mim]+. This is well-
reported on literature27,95, being the phenomenon occurring behind attributed to the higher 
molar volume and inherent higher hydrophobicity of ILs containing the acyclic cation 
cores, such as [N2,2,2,2]+. 
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Figure 14. Binodal curves of the IL/K3PO4-based ABS: [C2mim]Cl (), [C2mim][CH3CO2] (), [N2,2,2,2]Br 
(), [C2mim][DMP] (), [C2mim][N(CN)2] (),[C2mim][Tos] (+), [C2mim][CF3SO3] () + K3PO4 at (298 
± 1) K. Binodal curves adjusted using Eq. 5 are represented in dashed lines. The influence of IL’s structural 
features is provided separately in the insets to simplify the analysis. 
 
 
2.3.2. Benzoylecgnonine extraction 
HPLC is a well-established method to quantify benzoylecgnonine from diverse 
sources and matrices. Moreover, the use of IL-based ABS as sample pre-treatment 
approach was already proven to be compatible with the use of HPLC as the quantification 
technique58. The liquid chromatogram shown in Fig. 15 depicts the benzoylecgnonine 
standard peak (at 100 ppm), with a retention time (RT) of 24.3 min. This peak will be 
compared to that obtained for each of the coexisting phases, in order to identify and 
quantify this drug in human urine samples. In this sense, ABS with human urine containing 
the target drug and the respective blank controls were prepared. Figs. 16 and 17 display the 
chromatograms for top and bottom phases, respectively of either the drug-containing 
system or the control. The obtained chromatograms indicate that both blank and extraction 
systems present a similar profile (for top and bottom phases), with the absence of the 
benzoylecgnonine peak (RT = 24.3 min). Therefore, as the benzoylecgnonine 
concentration in the spiked urine is extremely low, the gathered data suggest that the ABS 
conditions here investigated were not suitable to develop a proper pre-concentration 
method for benzoylecgnonine; in fact, the target drug concentration remained below the 
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LOD of the analytical technique. It should be pointed out that the trace amounts of 
benzoylecgnonine applied are within the levels normally found in human fluids. Also, the 
strong alkaline environment inherent to the K3PO4 presence (pH = 13) can affect 
benzoylecgonine stability77. 
 
 
Figure 15. Liquid chromatogram of benzoylecgonine standard (100 ppm). 
 
 
Figure 16. HPLC chromatogram of the benzoylecgonine standard (black line), of the IL-rich phase of blank 
human urine-based ABS (blue line) and of the IL-rich phase of drug-containing human urine-based ABS 
(violet line). 
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Figure 17. HPLC chromatogram of the benzoylecgonine standard (black line), of the salt-rich phase of blank 
human urine-based ABS (blue line) and of the salt-rich phase of drug-containing human urine-based ABS 
(violet line). 
 
2.3.3. Harmine and harmaline extraction 
In order to assess the applicability of IL-based ABS as sample pre-
treatment/concentration of hallucinogens present in tea, it was necessary to develop and 
validate a novel MECK method. In this context, two main steps were performed: first, the 
establishment of MECK method conditions and second, the determination of the 
calibration curves. Fig. 18 depicts an eletropherogram of an approximately equimolar 
mixture of both alkaloids standards separated in an alkaline MEKC buffer containing 20 
mM of sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 % (v/v) methanol across a 20 
cm long capillary. Each of the alkaloids could be resolved to base-line in less than 6 
minutes. The order of migration was harmine followed by harmaline, being in agreement 
with the elution times for the single compounds in mixture. These migration times (4.75 
min for harmine and 5.05 min for harmaline) were significantly smaller and better 
resolutions were obtained than in a previous study96. This difference is likely a direct cause 
of the MEKC buffer herein adopted. In order to quantify both alkaloids, calibration curves 
were previously determined showing linearity over the specified range (80-120 ppm): 
harmine (y = 93.74x + 2570; R² = 0.9541) and harmaline (y = 478.2x – 1450; R² = 0.9811), 
where y and x represent the relationship between the peak area of the internal standard and 
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the corresponding calibration concentrations, respectively. Each standard was analysed in 
triplicate and the central point concentration was assessed ten times (100 ppm).  
  
 
Figure 18. Electropherogram of harmine and harmaline (100 ppm). Conditions: MEKC buffer containing 20 
mM sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 % (v/v) methanol. Capillary 20 cm to the detector 
and 50 ȝm i.d. , Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1) K,  
at a wavelength of 336 nm. 
 
After properly developing and validating the MEKC method, the pre-treated 
preparation of hallucinogens from Ayahuasca was extracted by [C2mim]Cl/K3PO4-based 
ABS and PEG 8000/NaPA 8000-based ABS with [C2mim]Cl as an electrolyte (Fig. 19). 
From visual analysis of Fig. 19, it is notorious that PEG 8000/NaPA 8000-based ABS 
exhibit lighter colour of top and bottom phase; this may indicates that less precipitation 
was obtained in this extraction due to the milder conditions of the separation (higher water 
content: 75.5 wt% vs. 45 wt%). Moreover, the darker aspect of the PEG 8000-rich phase 
may suggest that the hallucinogens are migrating towards this more hydrophobic phase; 
this is highly relevant as this type of ABS may be suitable to perform a pre-concentration 
stage of hallucinogens from aqueous media (tea matrix). However, the obtained 
electropherograms for the coexisting phases of each type of ABS (Figs. 20 to 23) do not 
provide quantitative/qualitative proofs. From the electropherograms of [C2mim]Cl/K3PO4-
based ABS coexisting phases (Figs. 20 and 21), it is possible to notice the presence of 
several overlapping peaks, precluding the identification and quantification of harmine and 
harmaline. On the other hand, no peaks were observed in the phases composing the 
polymeric ABS, impeding again the identification and quantification of both 
hallucinogens. Yet, the composition of Ayahuasca preparation is unknown, making harder 
to understand the profiles obtained in the electropherograms. Although the MEKC method 
Minutes
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was successfully applied to quantify with good resolution harmine and harmaline 
standards, its application in complex matrixes is a challenge, bringing the need for further 
studies for characterization of Ayahuasca preparation and other quantification methods.  
 
 
Figure 19. (a) [C2mim]Cl/K3PO4-based ABS extraction of hallucinogens from Ayahuasca  pre-treated 
sample, in which [C2mim]Cl and K3PO4 are the top and bottom phases, respectively. (b) PEG 8000/NaPA 
8000-based ABS extraction of hallucinogens from Ayahuasca pre-treated sample, in which PEG 8000 and 
NaPA 8000 are the top and bottom phases, respectively. 
 
Figure 20. Electropherogram of IL-rich phase of [C2mim]Cl/K3PO4-based ABS prepared using the 
Ayahuasca pre-treated sample. Conditions applied: MEKC buffer containing 20 mM sodium tetraborate, 
TBS (pH 9.40), 40 mM SDS, 10 % (v/v) of methanol. Capillary 20 cm to the detector and 50 ȝm i.d., 
Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1) K, wavelength 336 
nm. 
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Figure 21. Electropherogram of salt-rich phase of [C2mim]Cl/K3PO4-based ABS prepared using the 
Ayahuasca pre-treated sample. Conditions applied: MEKC buffer containing 20 mM sodium tetraborate, 
TBS (pH 9.40), 40 mM SDS, 10 % (v/v) of methanol. Capillary 20 cm to the detector and 50 ȝm i.d., 
Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1) K, wavelength 336 
nm. 
 
 
 
Figure 22. Electropherogram of PEG 8000-rich phase of PEG 8000/NaPA 8000-based ABS with [C2mim]Cl 
as electrolyte prepared using the Ayahuasca  pre-treated sample. Conditions: MEKC buffer containing 20 mM 
sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 % (v/v) of methanol. Capillary 20 cm to the detector and 
50ȝm i.d., Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, T = (293.1 ± 0.1) K,  
wavelength 336 nm. 
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Figure 23. Electropherogram of NaPA 8000-rich phase of PEG 8000/NaPA 8000-based ABS with 
[C2mim]Cl as electrolyte prepared using the Ayahuasca  pre-treated sample. Conditions applied: MEKC 
buffer containing 20 mM sodium tetraborate, TBS (pH 9.40), 40 mM SDS, 10 % (v/v) of methanol. Capillary 
20 cm to the detector and 50 ȝm i.d., Applied current: 70 ȝA, hydrodynamic injection 0.5 psi for 30 seconds, 
T = (293.1 ± 0.1) K, wavelength 336 nm. 
 
2.4. Conclusions and future work 
In summary, this work suggests that further studies should be performed in order to 
develop a proper IL-based ABS to concentrate benzoylecgonine from urine and 
hallucinogens from Ayahuasca  preparations. Although the general picture here created 
indicates that IL-based ABS were not successfully applied as pre-treatment routes, slight 
visual evidences show that polymeric ABS may be a promising alternative. Moreover, a 
novel MEKC method was successfully developed and validated for the quantification of 
the two hallucinogens harmine and harmaline in mixture, showing more advantageous 
characteristics than previously reported CE methods. 
The low levels of the target compounds (in ppm units for benzoylecgonine) are in 
fact the main drawback for the application of IL-based ABS. In this context, further 
conditions should be investigated, mostly by alternatively reducing the volume of each 
phase, in order to enhance the concentration step. Also, ILs can be used in SPME as 
extracting phases or even the use of ILs as hydrotropes to increase the drug solubility in 
aqueous solutions, thus overcoming the problems related to the LOD of the quantification 
techniques. 
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Chapter III  
 
FPLC Purification of recombinant L-
Asparaginase I from Saccharomyces 
cerevisiae expressed in Escherichia coli 
 
Abstract  
L-Asparaginase is known by its capacity to catalyse the hydrolysis of L-asparagine into L-
aspartic acid and ammonia. The effective depletion of L-asparagine results in a 
cytotoxicity scenario for leukemic cells. This enzyme has been thus clinically acceptable as 
an anti-tumour agent for the effective treatment of acute lymphoblastic leukemia and 
lymphosarcoma. This biopharmaceutical is produced by fermentation processes and then, it 
needs to be correctly separated from the contaminants produced in the fermentation 
process. Here, the Affinity Chromatography is applied as a novel approach to purify 
(His)6-tagged recombinant L-Asparaginase I from Saccharomyces cerevisiae expressed in 
Escherichia coli. The Affinity Chromatography was performed on a Fast Protein Liquid 
Chromatography (FPLC) system using a Ni2+-charged, 5 mL HiTrap IMAC FF. A linear 
gradient, running from 0 mM to 500 mM of imidazole at 5.0 mL.min-1 was performed in 
order to identify the lowest imidazole concentration of the elution buffer that extracts the 
higher amount of L-Asparaginase I. This concentration range was further used in a step 
imidazole gradient. Two-step concentrations of the initial imidazole concentration (32.0 
and 54.4 %) were applied. Polyacrylamide gel electrophoresis combined with silver 
staining and Nessler activity assay were used to confirm the presence of the purified L-
Asparaginase I (≈ 45 kDa). In the gradient step, the eluted recombinant L-Asparaginase I 
showed a high specific activity of 110.1 ± 0.3 IU.mg-1. Furthermore, a recovery of 81.03 ± 
0.01 % was obtained meaning a purification factor of 17 times. In this sense, the FPLC 
process has undoubtedly proved to be an efficient tool for the purification of this enzyme. 
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3.1. State-of-art 
 
Enzymes can be used to catalyze chemical reactions with high efficiency and 
specificity. Compared to conventional chemical processes, biocatalytic processes usually 
consume less energy, produce less waste and use less organic solvents. Moreover, the 
reactions are promoted at low or moderate temperatures, using preferably natural 
substrates, fermentation media or industrial wastes. The ability to evolve bioprocesses and 
bioproduction systems allows for major improvements in both economic and 
environmental performance. In this sense, enzyme production and purification by 
biotechnological industries permits a manufacturing facility to increase their profitability 
and capacity while maintaining or even reducing its environmental footprint. The major 
applications of enzymes are in food, pulp and paper, cosmetic and pharmaceutical 
industries. The medical and pharmaceutical application of enzymes covers a wide range of 
applications, including killing disease-causing microorganisms, prompting wound healing, 
and diagnosing certain diseases. In contrast to other industrial uses, where production is on 
a much larger scale; uses of medical and pharmaceutical enzyme applications generally 
require small quantities of highly purified enzymes. Enzymes and enzyme-generated 
products are administered to patients in very small doses; this is in order to avoid possible 
side effects97,98.  
 The L-asparaginase, L-asparagine amidohydrolase [EC 3.5.1.1] is an enzyme, which 
catalyzes the hydrolysis of the amino group L-asparagine, forming aspartic acid and 
ammonia (Eq.  6): 
 
 
(6) 
 
 The discovery of this enzyme started by Kidd (1953)99 remarkable observation, that 
Guinea pig serum had anti-tumor activity against several types of lymphoma in mice. The 
cause of this antileukemia activity was elucidated by Broome in 1963 proposed that the 
antileukaemia activity was attributed to the action of L-Asparaginase (L-ASNase)100. 
Nevertheless, only in 1967 the L-Asparaginase was isolated in quantities enough to be 
subjected to clinical trials towards to prove the anticancer activity101. Since then, the 
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interest in isolation and purification of L-ASNase has prominently improved, due to their 
pharmacological application.  
 L-ASNase was shown to be very useful in treating acute lymphocytic leukemia  
(ALL)102–104, acute myeloid leukemia105 and lymphomas106. Childhood acute lymphoblastic 
leukemia is a cancer of the blood and bone marrow107,108. In a healthy child, the bone 
marrow generates blood stem cells (immature cells) that become mature blood cells over 
time. A blood stem cell may become a myeloid stem cell or a lymphoid stem cell (Fig. 24). 
A myeloid stem cell becomes one of three types of mature blood cells: red blood cells that 
carry oxygen and other substances to all tissues of the body, platelets that form blood clots 
to stop bleeding and white blood cells that fight infection and disease. While a lymphoid 
stem cell becomes a lymphoblast cell and then one of three types of lymphocytes (white 
blood cells): lymphocytes that make antibodies to help fight infection; T lymphocytes that 
help B lymphocytes make the antibodies that help fight infection and natural killer cells 
that attack cancer cells and viruses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Overview of the normal human hematopoiesis109. Blood or Hematopoietic stem cells (HSCs) give 
rise to the myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, 
megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-cells, NK-cells) 
 
In a child with ALL, too many stem cells become lymphoblasts, B lymphocytes, or T 
lymphocytes, leading towards to an overproduction of cancerous, immature white blood 
cells, known as lymphoblast. These cells are continuously multiplying, causing damage 
and death by inhibiting the production of normal cells, such as red and white blood cells 
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and platelets, in the bone marrow and by spreading (infiltrating) to other organs. The 
American Cancer Society’s estimates in the United States for 2014, about 6020 new cases 
ALL (adults and children) and about 1440 deaths from ALL (adults and children), with 
much higher risk in children under 5 years old. Moreover, the average person’s lifetime 
risk of getting ALL is less than 1 in 750, being this probability slightly higher in males 
than in females and also higher in whites than in African Americans106–111.  
Treatment options for newly diagnosed childhood ALL include the following three 
steps: remission induction, also known as chemotherapy, post-remission treatment, and 
maintenance therapy. In the first two phases L-ASNase is prescribed and administered 
intramuscularly or intravenously103,104,106,112,113. The lymphoblast cells require a large 
amount of asparagine (Asn) to enhance their rapid, malignant growth, thus are dependent 
the extracellular level of asparagine to perform their protein synthesis. Furthermore, 
lymphoblast cells are not able to induce synthesis of asparagine synthetase, which is an 
intracellular, inducible enzyme and responsible by the de novo synthesis of asparagine. In 
addition, ASNase has the critical role by the Asn hydrolysis (Eq. 6), resulting in drastic 
diminishing of asparagine level, leading the lymphoblast cells into metabolic collapse and 
consequently death. In vitro tests have shown that the asparagine level in blood becomes 
undetectable in some minutes, when the activity of L-ASNase is the order of 0.70 IU.mL-1 
114
. The ability to reduce substantially the plasma level of asparagine and maintaining low 
for extended periods of time is the main feature responsible for the activity antineoplastic 
Asparaginase. 
However, there are some factors limiting the use of L-ASNase as chemotherapy 
agent. One of the factors to be considered is the requirement of daily doses of parenteral 
injections from 10 to 200 IU/Kg/day for a period of time, which may last for 21 days. 
Another factor to be considered is the toxic side effects, i.e. hyperglycemia, fall serum 
albumin, lipoproteins and fibrinogen, increased liver fat and some dysfunctions mild 
brain102,113,115–118. The most important limiting factor is the development of 
hypersensitivity to treatment. This hypersensitivity reactions ranging from small allergy in 
the drug injection area, bronchospasm and even anaphylactic shock, suggesting that the 
patient should not be repeatedly subjected to the same treatments type of L-ASNase, 
occurs between 5 and 50% of treated patients. 
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Aiming to alleviate at least some of these problems, researches focus in protein 
structural modification, due through genetic engineering or gene enhancement; and 
moreover, in conjugation of L-ASNase with biopolymers (e.g. polyethylene glycol, 
dextran, albumin and heparin)103,113,119–121. With these modifications, other features were 
acquired, for example, enhanced resistance to inactivation by proteolytic enzymes, 
improved stereochemical specificity, decreasing their antigenic capacity, increase in 
affinity towards the target cell and extensive maintenance enzyme activity. 
Nowadays, L-ASNase therapy is available in three preparations: two obtained from 
native forms, both bacterial and one preparation obtained from the E. coli enzyme 
conjugate with m-PEG 113. E. coli and Erwinia caratovora  are producing species of 
commercial L-Asparaginase from native forms (Elspar® from Merck and Erwinase® from 
Speywood, respectively). The two preparations exhibit similar mechanism of action and 
toxicity, differing in the pharmacokinetic properties 122,123.  
In this study, the L-ASNase source was Saccharomyces cerevisiae X2180-1A. This 
microorganism synthesizes two forms of L-ASNase: L-ASNase I, an intracellular 
constitutive enzyme, and Asparaginase II, an external enzyme which is secreted in 
response to nitrogen starvation. These two enzymes are biochemically and genetically 
distinct. Sarquis et al124, concluded that the usage of L-Asparaginase gene from an 
eukaryotic origin (yeast and filamentous fungi) can reduce the intensity of allergic 
reactions, due to post-translational modifications that occur in eukaryotic species, which 
are absent in prokaryotes beings. Therefore, it was studied the FPLC purification of L-
ASNase I from S. cerevisiae cloned and expressed in E.coli. Fast protein liquid 
chromatography (FPLC), is a form of liquid chromatography that is mainly used to analyze 
or purify mixtures of proteins. As in other forms of chromatography, separation is possible 
because the different components of a mixture have different affinities for two materials, a 
moving fluid (the "mobile phase") and a porous solid (the stationary phase). In FPLC the 
mobile phase is an aqueous solution or "buffer". The buffer flow rate is controlled by a 
positive-displacement pump and it is normally kept constant, while the composition of the 
buffer can be varied by drawing fluids in different proportions from two or more external 
reservoirs. The stationary phase is a resin composed of beads, usually of cross-linked 
agarose, packed into a cylindrical glass or plastic column. FPLC resins are available in a 
wide range of bead sizes and surface ligands depending on the application. In this research, 
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Figure 25. Schematic representation of the crystal L-asparaginase, resolution of 1.82 Å. 
(Extracted from Protein Data Bank, PDB code 2HIM). 
we used immobilized metal ion affinity chromatography resin, which is ideal for 
purification of histidine-tagged recombinant proteins, due to the interaction between 
negatively charged histidines with nickel cations (Ni 2+)125. 
 
3.2. Scopes 
The development of techniques and methods for the separation and purification of 
proteins and other biomolecules has been paramount to many advances in the 
biotechnology industry3,9,126. The main challenge for the production of biomolecules of 
pharmacological interest is the large-scale purification, because the effective purification 
methods in the laboratory are usually not scalable and industrial purification methods 
require higher purity. There is a real need to find an alternative, rentable and eco-friendly 
way for L-ASNase purification. Therefore, our intention is to purify L-ASNase I with a 
low number of purifying steps, obtaining a pure enzyme with high yields and specific 
activity, in order to be scaled-up en route for a promissory commercial pharmaceutically 
application. The use of affinity chromatography performed on a Fast protein liquid 
chromatography (FPLC) system as downstream purifying technique is easily justified, 
since can be readily scaled from analysis of milligrams of mixtures in columns with a total 
volume of 5 mL or less to industrial production of kilograms of purified protein in columns 
with volumes of many liters. Moreover, in contrast to direct competitor, HPLC, the buffer 
pressure used is relatively low, typically less than 5 bar, but the flow rate is relatively high, 
typically 1-5 mL.min-1, which is beneficial for protein purification.   
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3.3. Materials and Methods 
3.3.1. Protein Expression 
Initiators of ASNase I yeast (ASP1) were commissioned for the company Exxtend.  
For PCR amplification of this gene, was used the following protocol (Vf = 20 µL) : 1 µL 
of forward primer; 1 µL reverse primer ; 4 µl dNTPs (C = 1.25 mM); 0.4 µL MgSO4 (C = 
1 mM ) ; 6 µL Platinum® Pfx DNA Polymerase (Invitrogen™); 10 µL Milli-Q water and 1  
µl synthetic DNA of S. cerevisiae extracted with PureLink ® Pro 96 Genomic DNA 
Purification Kit (Invitrogen®) (ASP1 kit). Agarose gel to visualize the amplified samples : 
0.8 % agarose (0.32 g) in 1x TAE buffer (40 mL). Addition 1.5 µL of ethidium bromide to 
mark nucleic acid and placed in a horizontal electrophoresis system connected to a voltage 
source of Bio Rad®. 
  Digestion of the vector pET15b and ASNase I: Restriction enzymes or 
endonucleases Nde I and BamH I were used (New England Biolabs, NEB), allowing the 
formation of cohesive ends in the DNA structures that will bind. The samples were 
incubated at 37 °C for 2 hours to VF = 100 mL: 1 µL high- fidelity BamH I; 2 µl NdeI ; 10 
µL Buffer CutSmart 10X; 45 µL of ASNase I PCR product of yeast gene (ASP1) or 
bacterial vector pET15b and fully-filled with Milli-Q water. The purification of the 
digested samples is by cutting the agarose gel using the Illustra™ GFX™ PCR DNA and 
GEL BAND Purification Kit (GE®). 
Insert the ASP1 gene into vector: 2  µL Buffer 5X T4 DNA ligase (Invitrogen) ; 2 µL 
pet15b vector digested and purified ; 5 µL insert (ASP1) digested and purified ; 1 µL T4 
DNA ligase (1 IU.µL-1). Afterwards, the mixture is incubated for 2 hours at room 
temperature (~ 25 ° C) or overnight at 16 ° C. 
Bacterial Transformation: electrocompetent DH5α strain of E. coli bacteria stored in 
biofreezer -80 ° C were thawed and added to 1 µL of the ligation product; moved all 
content to electroporation cuvette which was placed in MicroPulser Electroporator (Bio 
Rad®) under the following conditions: 25 Ω conductance, 2.5 kV and 4.5-5.5 ms pulse. The 
transformation product was then resuspended in liquid LB medium (V = 1 mL) and 
incubated for 1 h at 37 °C under gentle agitation (70 rpm). 
Centrifugation and all plating of the inoculum in Carbenicillin LB solid medium (C = 
50 µg.µL-1). Plates were incubated for 16 h at 37 °C. Then the selection of colonies in the 
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plate to be incubated in LB broth (~ 3 mL) and carbenicillin (~ 3 µL) in Falcon tubes was 
performed. Incubation was carried out at 37 ° C for 16 h. 
Miniprep / alkaline lysis: Removal of plasmid + insert into bacteria by QIAprep Spin 
Miniprep Kit (Qiagen®) from 1.5 mL of culture medium, according to the manufacturer's 
instructions. 
Heterologous expression of ASNases: E. coli BL21 (DE3) strain stored in 
refrigerator biofreezer -80 °C were thawed and added: 1 µL purified plasmid with the 
insert; moved all content to electroporation cuvette, which was placed in MicroPulser 
Electroporator (Bio Rad®) under the following conditions: 25 Ω conductance, 2.5 kV and 
4.5-5.5 ms pulse. The transformation product was then resuspended in liquid LB medium 
(V = 1 mL) and incubated for 1 h at 37 °C under gentle agitation (70 rpm). The bacteria 
were grown in LB medium, supplemented with the appropriate antibiotics, at 37 °C until 
A600 = 0.6–0.7. When the bacteria are in log-phase, was added IPTG (Isopropylthio - β -D- 
galactoside) to induce transcription from the T7 promoter and consequently allow the 
production of ASNase I.  
 
 
3.3.2. Cell lysis and sample pre-treatment 
The sample pre-treatment was carried on by a chemical lysis procedure; herein cell 
pellets from genetically transformed E. coli were resuspended with BugBuster (10 mL per 
g cell), following the ensuing procedure: mixed gently for 20 minutes, in order to avoid 
foam formation; centrifuge at 16000 x g for 20 minutes at 4 °C; discard the pellet and the 
supernatant vacuum filter membrane (0.45 ȝm); add 20 mM final concentration imidazole 
to the filtered sample and finally apply sonication.  
 
3.3.3. Ni2+- affinity chromatography 
Affinity chromatography was performed on FPLC™ System (ÄKTApurifier, GE 
Healthcare) using a Ni2+-charged, 5 mL HiTrap IMAC FF column, ideal for purification of 
histidine-tagged recombinant proteins (Fig. 26).  
A linear gradient, running from 0 mM to 500 mM of imidazole at 5.0 mL.min-1 was 
performed in order to identify the lowest imidazole concentration of the elution buffer that 
extracts the higher amount of L-ASNase I. This concentration range was further used in a 
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step imidazole gradient, in which two-step concentrations of the initial imidazole 
concentration (32.0 and 54.4 %) were applied. The eluted fractions were collected with a 
fixed volume of 1.5 mL per fraction. The binding buffer (20 mM sodium phosphate buffer 
at pH = 8.0, 500 mM NaCl) and elution buffer (20 mM sodium phosphate buffer pH 8.0, 
500mM NaCl, 500mM imidazole) were used in L-ASNase I purification. 
 
 
 
  
 
 
 
 
 
 
 
3.3.4. Nessler activity assay 
The determination of enzymatic activity was performed by Nessler activity assay and 
expressed in IU.mL-1 127. The samples are previously centrifuged 4000 x g for 20 min at 
4°C, lysed and desalted with 20 mM Tris-HCl buffer at pH 8,6 (in order to remove 
imidazole). The sample volume of 0.1 mL is incubated at 37 °C for 30 min in 1 mL of Tris 
buffer (50 mM, pH 8.6) with 0.1 mL of L-asparagine (189 mM) and 0.9 mL of Milli-Q 
water, the reaction is stopped with the addiction of 0.1 mL trichloroacetic acid (TCA) 1.5 
M. The tubes are shaken by inversion and centrifuged for 2 min to clarify. After staining 
step, 0.2 ml supernatant, 4.3 ml of Milli-Q water and 0.5 mL of Nessler reagent are mixed 
by inversion for 1 min and then measured in microplate reader at Ȝ = 436 nm. To prepare 
the standard curve the amount of L-asparagine is replaced with (0.25, 0.50 and 1.0 mL) 
solution of ammonium sulfate (6 mM) and supplemented with Milli-Q water to 2.2 mL 
final volume.  In order to remove the possible interferences, two blanks were made for each 
sample. Moreover, at least three samples of each enzymatic activity measure were 
prepared, decreasing the associated error of enzymatic activity quantification. 
 
Figure 26. (a) FPLC™ (System ÄKTApurifier) formed by Pump P-900, Monitor UV-900, Monitor 
UPC-900, Valve INV-907, Mixer M-925 and Valves SV-903, FV-923 (b) HiTrapTM 5 mL IMAC FF 
column 
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The enzymatic activity (EA) was calculated considering Eq. 7 and is expressed in 
IU.mL-1 enzyme: 
                                       (7) 
where t corresponds to time of assay in minutes and Ve is the volume in mL of ASNase I 
used. 
The specific activity (SA) was calculated following the Eq. 8 and is expressed in 
IU.mg-1 protein: 
                        (8) 
where EA corresponds to enzymatic activity in IU.mL-1 and [P] is the concentration of 
protein in mg of protein per mL of ASNase I used.  
  To evaluate the FPLC purification yield, two parameters were calculated, namely 
recovery and purification factor (PF), calculated by the following equations (Eq. 9 and 10) 
                                   (9) 
                         (10) 
where (EA)f corresponds to enzymatic activity of the purified sample in IU/mL and (EA)I 
to enzymatic activity of the initial sample in IU/mL, meanwhile the (SA)f and (SA)i values 
are related to specific activity of the purified and the initial sample. 
 
 
3.3.5. Protein quantification method 
The absorbance assay, measuring the absorbance at Ȝ = 280 nm, was used to estimate 
total protein concentration. This method is useful, due to the fact that the sample can be 
recovered and is the rapidest and most straightforward protein quantification method. A 
BSA calibration curve (bovine serum albumin, lyophilized powder, ≥ 96 wt%, Sigma®) 
was used to determine the protein concentration in the samples. 
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3.3.6. Polyacrylamide gel electrophoresis combined with silver staining 
After FPLC purification, the samples are analyzed by SDS-PAGE technique. A 
sample volume of 20 ȝL is applied in polyacrylamide-gel, formed by 12% polyacrylamide-
SDS (10 x 10.5 cm x 0.75 mm thick) under reducing conditions, according to the method 
of Laemmli128. The electrophoresis was performed at 120 V for approximately 1.5h using a 
vertical (Bio Rad®) system. Protein markers of different molar masses are bought in Bio 
Rad. The gels are silver stained for visualization of protein bands using the Silver Staining 
Kit (Amersham Pharmacia Biotech®) following the manufacturer's instructions. 
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3.4. Results and discussion 
FPLC purification was performed in two different stages. In the first stage a linear 
gradient, running from 0 mM to 500 mM of imidazole at 5.0 mL.min-1 was performed in 
order to identify the lowest imidazole concentration of the elution buffer that extracts the 
higher amount of L-ASNase I. By the analysis of the Fig. 27, there are two regions 
(fractions 14-18 and 20-31), in which a slightly increase in A280nm was observed, this might 
indicate the elution of ASNase I from the nickel column. The washout unbound proteins, 
which not interact with the column, were eluted in fractions 4-5, where an intense peak of 
absorbance was obtained (this peak is not showed in Fig 27). Therefore, Nessler ASNase 
activity assay and electrophoresis were used to confirm the presence of the purified L-
Asparaginase I (≈ 45 kDa). Through the Fig. 28 and the Table 2, we confirm that fractions 
4-5 contain the proteins that have no interaction with nickel column and are immediately 
eluted, for this reason very low specific ASNase I activity were obtained (0.02  ± 0.00 
IU.mg-1). Moreover, the purified fractions 20-31 exhibit the highest specific activity (6.61 
± 0.08 IU.mg-1) six times more than the fractions 14-1. Furthermore, by electrophoresis 
analysis, we can see that the bands from 22-31 are more intense, meaning that higher 
concentrations of ASNase I were purified in those fractions. Hence, it was determined to 
choose the imidazole concentration in the elution buffer that extracted fractions 23-30, 
respectively (32.0 and 54.4 % of the initial imidazole concentration in the elution buffer). 
This concentration range was further used in a step imidazole gradient, in which two-step 
concentrations of the initial imidazole concentration (32.0 and 54.4 %) were applied. 
 
 
 
 
 
 
  
 
 
 
 
Figure 27. Linear gradient of imidazole used in FPLC purification, obtained from FPLC software.  
The blue line, corresponds to absorbance at 280 nm. The black boxes (fractions 14-18 and 20-31) 
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Table 2.  FPLC purification with imidazole linear gradient (0 mM - 500 mM) at 5.0 mL.min-1. Fractions 
eluted with ASNase I activity are shown, along with protein concentration, enzymatic activity and specific 
activity values. 
Sample Protein 
Concentration 
 (mg.mL-1) 
Enzymatic activity 
(IU.mL-1) 
Specific activity 
(IU.mg-1) 
Fractions 4-5 3.5442 ± 0.0002 0.0173  ± 0.0003 0.02  ± 0.00 
Fractions 14-18 0.0536 ±  0.0107 0.4862  ± 0.0001 0.49  ± 0.00 
Fractions 20-31 0.0170 ±  0.0021 6.6102  ± 0.0013 6.61  ± 0.08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The second stage, the imidazole concentration in the elution buffer was optimized 
using a two-steps concentration. In the Table 3, it is evident that the elution fractions 
obtained in two-steps approach are much more purified than the ones obtained by linear 
gradient purification. Moreover, the eluted fractions 38-42 (total volume = 7.5 mL) were 
purified with higher specific ASNase I activity (110.06 ± 0.34 IU.mg-1) and improved 
yields: a recovery of 81.03 ± 0.01 % was obtained, meaning a purification factor of 17 
times. The electrophoresis (Fig. 29) is in good agreement with the previously results, 
confirming that the purified fractions have ASNase I in high concentrations.   
116.0 
66.2 
45.0 
35.0 
25.0 
18.4 
PM 
 
 
Figure 28. Polyacrylamide gel electrophoresis combined with silver staining, showing the 
purified samples from linear step FPLC purification. The black boxes highlight the wash-
out unbound proteins (second lane) and histidine-tagged ASNase bands (~ 45.0 KDa). In 
the different lanes are represented the eluted fractions, PM refers to Protein Markers. 
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Table 3.  FPLC purification with two-step concentrations of the initial imidazole concentration (32.0 and 
54.4 %) were applied.at 5.0 mL.min-1. Fractions eluted with ASNase I activity are shown, along with protein 
concentration, enzymatic activity, specific activity, purification factor and recovery parameters.  
Sample Protein 
Concentration 
 (mg.mL-1) 
Enzymatic 
activity 
 (IU.mL-1) 
Specific 
activity 
(IU.mg-1) 
Purification 
factor 
Recovery 
(%) 
Fermentation 
broth extract 0.3807 ± 0.0019 2.4898 ± 0.0014 6.52 ± 0.01 
1.00 
         
100.00 
 
Fractions 28-32 0.0208  ± 0.0050 1.6022 ± 0.0081 79.87 ± 1.13 12.24 64.00 
Fractions 33-37 0.0334 ± 0.0005 1.5103 ±0.0128 43.99 ± 0.43 6.75 60.66 
Fractions 38-42 0.0185 ± 0.0025 2.0174 ±0.0052 110.06 ± 0.34 16.88 81.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45.0 kDa 
Figure 29. Polyacrylamide gel electrophoresis combined with silver staining, showing 
the purified samples from two-step FPLC purification. The brown box highlights the his-
tagged ASNase bands (~ 45.0 KDa). In the different lanes are represented the eluted 
fractions, PM refers to Protein Markers. 
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3.5. Conclusions 
In summary, the optimized two-steps FPLC purification method, allows a successful 
extraction and purification of L-ASNase I from S cerevisiae expressed in E.coli. This novel 
downstream method appears to be an eco-friendly and rentable alternative to purify L-
ASNase I, which can be easily scaled up for industrial purposes. Upper yields and recovery 
were obtained; making FPLC an efficient tool for the purification of this particular 
enzyme.  
 
 
3.6. Future work 
Further studies in FPLC parameters, such as the fraction volume, pump pressure, 
initial volume injected, elution and binding buffer formulations should be achieved in 
order to even optimize more the purifying yields.  
By the analysis of our results, the most purified fraction exhibit a lower specific 
activity (110 IU.mg-1), when compared to the commercial ASNase formulations available 
in the market. Erwinaze® (Asparaginase from Erwinia chrysanthemi) and ELSPAR® 
(Asparaginase from recombinant E. coli) contains 225 IU.mg-1, data displayed in Product 
Datasheet - Active Asparaginase full length protein ab73439. Through the decreasing of 
the fraction volume, higher specific activities will be reached, nearby the values of 
commercial L-ASNases. 
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General Conclusions 
  
Aqueous biphasic systems and Fast Protein Liquid Chromatography were the two 
downstream techniques applied and studied in this research. When comparing the two 
techniques, it becomes notorious that in one hand ABS are high-throughput, low-resolution 
techniques and in the other hand FPLC is a high-resolution low-throughput technique. For 
that reason, ABS were used in purification of probe molecules with no contaminants 
presented and moreover used in toxicological field. Meanwhile, FPLC was applied in 
ASNase I purification, in order to obtain high yields and high purity levels to insure the 
product stability; since there are stringent quality requirements for products used for 
pharmaceutical purposes.  
A novel downstream ABS technique was successfully developed, in which it’s used 
low amounts of IL (0.1 wt%, for example) as an electrolyte that promote phase split of 
polymer components. Moreover, this new downstream technology proved to be 
advantageous to boost the extractive performance of different bio(molecules) including Cyt 
c and CA. Additionally, it is our intention to apply these types of ABS in the purification 
of added-value compounds from real matrices, such as fermentation media or marine raw 
materials. 
Although, ABS were previously successful as an analytical tool for forensic 
toxicology field, e.g. bisphenol A purification from synthetic urine, their application is still 
scare, mainly because to the several obstacles that ABS faces. In this case ABS were not an 
advantageous single-step pre-treatment and extraction technique of both hallucinogens and 
cocaine biomarker from Ayahuasca and urine, respectively. This may be explained due to 
the following downstream challenges that this technique faces: toxins/drugs concentration 
is in minor levels (in the order ng.mL-1) and both urine and Ayahuasca are two highly 
complex matrixes. For that reason, a higher-resolution downstream technique is needed in 
these cases. 
The ASNase I purification from fermentation broth fulfilled the RIPP procedure. In 
which firstly, low-resolution techniques such as centrifugation, vacuum filtration and 
sonication were applied and only afterwards the high -resolution technique:  FPLC.  
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Appendix A 
 
Probe Molecules – CA and Cyt c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1 - Speciation curve of CA as a function of pH. This content was adapted from the Chemspider 
chemical database. At orange it is represented the curve related to the pH of the system (between 7-8), in 
which the CA is negatively charged. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.2 - Speciation curve of Cyt c as a function of pH. This content was adapted from the 
Chemspider chemical database. At orange it is represented the curve related to the pH of the system 
(between 7-8), in which the Cyt c is positively charged. 
 
 
 
 
 
 
Experimental weight fraction data, respective correlations (adjusted 
parameters A, B and C) and binodal curves in mass fraction units 
 
Table A.1: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of  NaPA 8000 (1) + PEG 8000 (2) + H2O systems 
determined in the present work. 
 
5 wt% [N2,2,2,2]Br 
 
A ± std = 42.79 ± 0.75 
B ± std = -0.736 ± 0.015 
C ± std = 1.1× 10-3 ± 1.8× 10-4 
R2 = 0.9969 
5 wt% [N2,2,2,2]Cl 
 
A ± std = 47.87 ± 0.89  
B ± std = -0.762 ± 0.013  
C ± std = 1.4 × 10-4 ± 5.8× 10-5 
R2 =  0.9942 
5 wt% [C2mim][DMP] 
 
A ± std = 38.71 ± 1.44  
B ± std = -0.592± 0.025 
C ± std = 6.8× 10-4 ± 1.5× 10-4 
R2 =  0.9926 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
0.50 25.70 7.09 3.55 0.51 29.17 1.10 20.48 
0.72 23.06 7.64 3.06 0.68 25.86 1.63 18.83 
0.85 21.51 8.13 2.30 0.87 23.22 2.25 16.03 
1.03 20.33 8.72 2.17 0.97 21.39 2.14 15.82 
1.37 18.11 20.92 0.62 1.20 19.94 2.23 15.70 
1.52 17.09 7.09 3.55 1.38 18.56 2.46 15.10 
1.73 15.28 7.64 3.06 2.25 15.06 2.38 15.03 
1.96 14.43 8.13 2.30 2.40 14.65 2.55 14.73 
2.18 13.65 8.72 2.17 2.42 14.38 2.78 14.55 
2.71 12.84 20.92 0.62 2.45 14.71 2.72 14.51 
2.78 12.52  
 
2.50 14.59 2.84 14.17 
2.86 12.30   2.56 14.23 2.99 13.67 
2.94 12.12   2.64 14.07 3.24 13.26 
3.06 11.68   2.68 13.30 3.24 13.11 
3.19 11.31   2.72 13.76 4.00 11.15 
3.27 10.99   2.83 13.63 4.48 10.03 
3.35 10.69   2.96 13.44 8.09 5.12 
3.50 10.51   2.98 12.51   
3.60 10.37   3.08 13.19   
3.72 9.75  
 3.23 12.36   
3.85 9.45  
 3.36 11.60   
4.00 9.22  
 3.45 11.77   
4.14 8.86  
 3.55 11.20   
4.26 8.73  
 3.70 11.23   
4.40 8.35  
 3.88 10.77   
4.60 7.96  
 4.01 10.42   
4.80 7.69  
 4.23 9.51   
4.90 7.06  
 4.68 8.66   
5.10 7.04  
 5.23 8.35   
5.14 6.81   5.33 8.01   
5.40 6.40   5.62 7.60   
5.67 6.02   6.16 7.22   
5.91 5.59   14.31 1.73   
6.33 5.08   16.48 1.25   
6.68 4.31  
 19.29 0.43  
 
Table A.2: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of  NaPA 8000 (1) + PEG 8000 (2) + H2O systems 
determined in the present work.  
 
 
 
 
5 wt% [C2mim][CF3SO3] 
 
A ± std = 48.54± 0.99  
B ± std = -0.951 ± 0.017  
C ± std = 8.5× 10-4 ± 2.2× 10-4 
R2 =  0.9968 
5 wt% [C2mim]Cl 
 
A ± std = 45.16 ± 2.22  
B ± std = -0.874 ± 0.032 
C ± std = 2.0× 10-4 ± 1.0× 10-4 
R2 =  0.9958 
5 wt% [C2mim][CH3SO3] 
 
A ± std = 47.86 ± 1.06  
B ± std = -0.765 ± 0.019  
C ± std = 4.0× 10-4 ± 3.0× 10-4 
R2 =  0.9988 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
0.68 22.44 4.68 5.96 1.52 15.52 0.79 24.18 
0.90 19.43 4.42 5.88 1.74 13.75 1.17 20.98 
1.21 16.75 4.41 5.78 2.09 12.89 1.39 19.55 
1.37 15.55 4.48 5.65 2.69 11.13 1.53 18.35 
1.55 14.84 5.21 4.99 2.92 10.36 2.19 15.56 
1.69 13.96 6.68 3.41 3.68 8.00 2.49 14.47 
1.83 13.36   4.33 7.39 3.16 12.27 
2.01 12.83   4.64 6.70 3.46 11.12 
2.16 12.33   5.09 5.87 3.47 11.11 
2.22 11.87   5.85 5.46 3.88 10.17 
2.30 11.28   6.23 4.81 4.40 9.14 
2.48 10.71   13.59 1.20 4.68 8.83 
2.58 10.39          5.10 
 
8.28 
2.69 10.00       
3.14 9.21       
2.93 8.92       
3.48 8.29       
3.29 8.24       
3.37 7.93       
3.71 7.80       
3.67 7.56       
3.79 7.48       
3.78 7.30       
3.90 7.15       
3.78 7.09       
4.02 7.08       
3.88 6.94       
4.12 6.83       
3.98 6.77       
4.03 6.66       
4.18 6.45       
4.36 6.33       
4.21 6.32       
4.29 6.21       
4.36 6.02       
 Table A.3: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of  NaPA 8000 (1) + PEG 8000 (2) + H2O systems 
determined in the present work. 
 
 
 
5 wt% [C2mim][Tos] 
 
A ± std = 74.28 ± 1.28  
B ± std = -1.216 ± 0.013  
C ± std = 2.4× 10-4 ± 1.2× 10-4 
R2 =  0.9976 
5 wt% [C2OHmim]Cl 
 
A ± std = 65.89 ± 2.46  
B ± std = -0.955 ± 0.037 
C ± std = 7.8× 10-4 ± 3.3× 10-4 
R2 =  0.9947 
5 wt% [C2mim][CH3CO2] 
 
A ± std = 60.88 ± 2.13 
B ± std = -0.928 ± 0.028  
C ± std = 5.0× 10-4 ± 1.0× 10-4 
R2 =  0.9984 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
0.71 27.20 7.08 2.72 0.42 35.90 0.97 24.03 
0.86 23.83 7.99 1.97 0.54 31.02 1.24 21.57 
1.20 20.01 8.66 1.63 1.06 26.33 1.29 21.51 
1.37 18.42 9.42 1.26 1.76 18.45 1.42 20.05 
1.59 15.31 11.14 0.61 2.11 16.88 1.67 17.97 
1.74 14.31   2.16 16.41 2.06 16.66 
1.92 13.74   2.29 15.26 2.32 15.21 
2.01 12.96   4.00 8.59 4.15 8.67 
2.12 12.40   4.74 6.73 4.56 7.70 
2.17 12.02   4.98 6.45 5.00 7.00 
2.53 10.64   5.35 5.97 6.84 4.37 
2.62 10.23   6.14 5.22 7.92 3.58 
2.68 10.02   6.77 4.59 8.80 3.04 
2.71 9.81   7.36 4.02 12.20 1.19 
2.78 9.55   7.99 3.19   
2.87 9.41   9.07 2.48   
2.87 9.14       
2.92 8.88       
3.12 8.70       
3.17 8.28       
3.19 8.55       
3.37 8.07       
3.44 7.92       
3.48 7.80       
3.54 7.68       
3.57 7.54       
3.61 7.42       
3.65 7.30       
3.76 7.21       
3.82 7.11       
3.88 6.98       
3.91 6.86       
3.99 6.76       
6.78 3.12       
6.90 3.00       
Table A.4: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of  NaPA 8000 (1) + PEG 8000 (2) + H2O systems 
determined in the present work. 
 
 
 
5 wt% [C2mim][N(CN)2] 
 
A ± std = 38.22 ± 0.99  
B ± std = -0.911± 0.025 
C ± std = 2.8× 10-4 ± 6.0× 10-5 
R2 =  0.9949 
5 wt% [Ch]Cl 
 
A ± std = 33.15 ± 1.21  
B ± std = -0.654 ± 0.034 
C ± std = 1.8× 10-3 ± 3.2× 10-4 
R2 =  0.9976 
5 wt% NaCl 
 
A ± std = 8.66 ± 0.16 
B ± std = -0.419 ± 0.015  
C ± std = 9.3× 10-4 ± 1.8× 10-4 
R2 =  0.9845 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
0.50 20.80 0.50 20.65 0.45 6.63 2.87 4.18 
0.69 18.15 0.83 18.38 0.55 6.78 2.93 4.24 
0.81 16.73 1.25 15.96 0.59 6.17 3.00 4.13 
0.89 15.61 1.77 13.81 0.72 6.41 3.09 4.03 
1.05 14.53 2.48 11.98 0.83 5.82 3.14 3.90 
1.24 13.38 2.69 10.63 1.03 5.50 3.22 3.92 
1.43 12.66 5.39 4.86 1.13 5.46 3.32 3.99 
1.54 11.93 6.20 4.48 1.15 5.54 3.38 3.93 
1.75 11.44 7.04 3.20 1.18 5.46 3.52 3.98 
1.95 10.80 11.61 0.65 1.21 5.41 3.67 3.82 
2.09 10.36   1.22 5.31 3.75 3.90 
2.33 9.93   1.23 5.39 3.94 3.76 
2.42 9.42   1.26 5.42 4.04 3.46 
2.52 9.07   1.29 5.35 4.27 3.34 
2.68 8.81   1.33 5.12 4.49 3.25 
2.75 8.64   1.41 5.14 4.84 3.02 
2.88 8.34   1.44 5.10 5.15 2.91 
3.00 8.10   1.50 5.14 5.38 2.74 
3.04 7.96   1.54 5.06 5.43 2.82 
3.06 7.76   1.60 5.03 5.74 2.64 
3.07 7.59   1.66 5.00 5.83 2.54 
3.33 7.35   1.70 4.91   
3.37 7.12   1.77 4.83   
3.47 6.98   1.85 4.79   
3.42 6.94   1.92 4.75   
3.51 6.52   2.01 4.75   
3.62 6.50   2.05 4.69   
3.71 6.45   2.12 4.60   
3.80 6.11   2.19 4.56   
3.93 6.10   2.31 4.53   
4.01 6.00   2.40 4.44   
4.15 5.73   2.46 4.49   
0.50 20.80   2.52 4.52   
0.69 18.15   2.69 4.56   
0.81 16.73   2.81 4.28   
Table A.5: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of  NaPA 8000 (1) + PEG 8000 (2) + H2O systems 
determined in the present work. 
  
 
 
 
 
5 wt% Na2SO4 
 
A ± std = 12.69 ± 0.18  
B ± std = -0.679± 0.019 
C ± std = 6.3× 10-3 ± 1.6× 10-3 
R2 =  0.9938 
2.5 wt% NaCl 
 
A ± std = 11.90 ± 0.18  
B ± std = -0.589± 0.019 
C ± std = 1.1× 10-3 ± 4.6× 10-4 
R2 =  0.9964 
0.1 wt% NaCl 
 
A ± std = 38.82 ± 2.71 
B ± std = -0.556 ± 0.039  
C ± std = 8.3× 10-4 ± 1.2× 10-4 
R2 =  0.9985 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
0.11 10.73 0.15 9.66 3.34 13.65 
0.15 9.74 0.30 8.69 3.48 13.36 
0.20 9.06 0.28 8.50 3.62 12.97 
0.30 8.51 0.51 8.00 3.85 12.42 
0.40 8.20 0.48 7.63 3.99 12.04 
0.47 7.82 0.60 7.30 4.18 11.81 
0.56 7.58 0.85 7.22 4.40 11.09 
0.66 7.28 2.60 4.53 4.80 10.56 
0.76 6.75 2.75 4.40 4.87 10.36 
0.99 6.46 2.88 4.36 5.10 9.88 
1.10 6.23 3.05 4.12 5.42 9.33 
1.24 5.93 3.13 4.06 5.66 8.97 
1.33 5.76 3.19 3.98 5.83 8.63 
1.40 5.61 3.31 3.93 6.01 8.41 
1.49 5.49 3.42 3.84 6.11 8.12 
1.57 5.37 3.61 3.74 6.35 7.84 
1.65 5.21 3.76 3.57 6.42 7.51 
1.70 5.14 3.99 3.43 6.62 7.19 
1.72 5.00 4.08 3.28   
1.83 4.91 4.24 3.23   
1.90 4.76 4.34 3.23   
2.02 4.68 4.90 2.92   
2.09 4.58     
2.12 4.49     
2.15 4.38     
2.23 4.26     
2.38 4.09     
2.43 3.99     
2.52 3.91     
2.70 3.76     
2.85 3.25     
      
      
      
      
Table A.6: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of  NaPA 8000 (1) + PEG 8000 (2) + H2O systems 
determined in the present work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5 wt% [C2mim][N(CN)2] 
 
A ± std = 56.33 ± 0.64  
B ± std = -0.998± 0.010 
C ± std = 1.0× 10-3 ± 1.3× 10-4 
R2 =  0.9986 
0.1 wt% [C2mim][N(CN)2] 
 
A ± std = 50.20 ± 5.94  
B ± std = -0.637± 0.069 
C ± std = 6.0× 10-4 ± 3.0× 10-4 
R2 =  0.9923 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
0.41 29.69 5.56 4.48 2.78 17.05 
0.72 24.57 5.73 4.01 3.47 15.27 
1.05 19.82 5.95 3.79 3.49 14.74 
1.26 18.61 6.18 3.55 3.81 13.63 
1.35 17.24 6.43 3.26 3.85 14.18 
1.56 16.17   4.03 13.17 
1.88 14.55   4.05 13.45 
1.93 13.72   4.32 12.60 
2.09 13.18   4.49 12.28 
2.18 12.70   4.58 11.89 
2.18 13.04   4.84 11.58 
2.28 12.25   5.09 11.06 
2.29 11.70   5.34 10.47 
2.36 12.05   5.66 9.98 
2.44 11.78   6.09 8.88 
2.54 11.52     
2.68 10.72     
2.74 10.72     
2.79 10.47     
2.88 10.11     
2.96 9.83     
3.10 9.14     
3.25 8.98     
3.36 8.56     
3.52 8.42     
3.65 7.84     
3.86 7.58     
3.99 7.23     
4.17 6.91     
4.31 6.65     
4.49 6.42     
4.69 6.03     
4.80 5.85     
5.03 5.51     
5.23 5.03     
Figure A.3 - Phase diagram of the PEG 8000/NaPA 8000-based ABS containing 5 wt% of electrolyte (either common salts or ILs): NaCl (), 
Na2SO4 (), [C2mim][N(CN)2] (), [C2mim][Tos]  (+), [C2mim][CF3SO3] (), [C2mim]Cl (), [Ch]Cl (), [C2OHmim]Cl (), 
[C2mim][CH3CO2] (), [N2,2,2,2]Br (), [C2mim][CH3SO3] (), [N2,2,2,2]Cl (), [C2mim][DMP] ().Binodal curves adjusted using Equation 
1 are represented in dashed lines. 
Figure A.2 - Phase diagram of PEG 8000/NaPA 8000-based ABS at different electrolytes’ 
concentration: 5 wt% of NaCl (▲), 2.5 wt% of NaCl (), 0.1 wt% NaCl ( ), 5 wt% of 
[C2mim][N(CN)2] (), 2.5 wt% of [C2mim][N(CN)2] () and 0.1 wt % [C2mim][N(CN)2] 
().Binodal curves adjusted using Equation 1 are represented in dashed lines. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.4- The colour of CA and Cyt c allows visual inspection of the phase preferences. 
 
 
                                                
 
                                   
Table A.7: ABS pH of both top (PEG-rich) phase and bottom 
(NaPA-rich) phase and partition coefficient of IL and CA for all 
electrolytes used. 
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Harmine and Harmaline  
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1. – Harmine and harmaline chemical structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental weight fraction data, respective correlations (adjusted 
parameters A, B and C) and binodal curves in mass fraction units 
 
Table B.1: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of IL (1) + K3PO4 (2) + H2O systems determined in the 
present work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 [N2,2,2,2]Br 
 
A ± std = 97.71 ± 3.31 
B ± std = -0.373 ± 0.012 
C ± std = 5.2× 10-5 ± 3.5× 10-6 
R2 = 0.9990 
 [C2mim][DMP] 
 
A ± std = 93.54 ± 3.81 
B ± std = -0.343± 0.013 
C ± std = 2.3× 10-5 ± 2.6× 10-6 
R2 =  0.9998 
100 w1 100 w2 100 w1 100 w2 
34.76 7.52 31.73 9.55 
32.93 8.01 28.32 11.44 
30.00 9.37 25.54 13.18 
27.63 10.24 22.47 15.20 
26.55 10.82 19.58 17.68 
26.03 11.16 18.13 18.80 
24.39 12.13 17.56 19.23 
24.09 12.22 17.41 19.35 
23.08 12.91 17.07 19.67 
22.75 12.99   
21.77 13.62   
21.39 13.89   
21.07 14.02   
20.55 14.40   
20.14 14.66   
19.59 14.99   
19.04 15.20   
18.55 15.60   
18.37 15.63   
17.56 16.06   
17.20 16.29   
16.90 16.51   
16.61 16.68   
16.44 16.86   
16.14 17.06   
15.95 17.20   
15.60 17.49   
15.40 17.61   
15.30 17.67   
   
 
 
   
Table B.2: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of IL (1) + K3PO4 (2) + H2O systems determined in the 
present work. 
 
 
 
 
 
[C2mim]Cl 
 
A ± std = 75.61 ± 1.22 
B ± std = -0.328 ± 0.006 
C ± std = 2.8× 10-5 ± 1.1× 10-6 
R2 = 0.9993 
[C2mim][CF3SO3] 
 
A ± std = 89.88 ± 4.29  
B ± std = -0.349 ± 0.025 
C ± std = 2.9 × 10-4 ± 6.4× 10-5 
R2 =   0.9972 
 [C2mim][CH3CO2] 
 
A ± std = 51.07 ± 3.85 
B ± std = -0.207± 0.020 
C ± std = 3.7× 10-5 ± 1.8× 10-6 
R2 =  0.9999 
100 w1 100 w2 100 w1 100 w2 100 w1 100 w2 
38.73 4.18 47.63 3.19 18.03 17.06 
31.37 7.14 43.56 4.11 17.47 17.64 
25.03 10.29 42.22 4.47 16.97 18.10 
23.37 11.51 41.28 4.63 15.67 19.39 
21.55 13.05 40.72 4.80 15.37 19.61 
20.02 14.42 39.99 4.99 13.78 21.25 
18.42 15.88 38.63 5.16 13.34 21.70 
17.04 17.15 38.27 5.31 13.09 21.94 
15.76 18.40 37.71 5.57 12.63 22.36 
14.58 19.56 35.39 6.06 12.45 22.58 
13.55 20.57 33.65 6.67 11.76 23.30 
12.68 21.43 33.00 6.91 11.57 23.49 
11.82 22.34 32.25 7.05   
10.78 23.44 31.80 7.11   
10.06 24.24     
9.16 25.24     
8.23 26.41     
7.37 27.50     
6.54 28.65     
5.60 30.04     
  
  
  
  
  
  
  
  
 
 
  
  
 
 
  
  
 
 
  
  
 
 
  
  
 
 
  
  
 
 
  
  
 
 
 
   
 
 
 
     
 Table B.3: Parameters obtained through the Merchuk equation with the respective 
standard deviations (std) and correlation factors (R2) along with the weight fraction data 
(w) for the systems composed of IL (1) + K3PO4 (2) + H2O systems determined in the 
present work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[C2mim][Tos] 
 
A ± std = 89.40 ± 1.33  
B ± std = -0.342 ± 0.007 
C ± std = 1.0 × 10-4 ± 5.5× 10-6 
R2 =   0.9994 
 [C2mim] [N(CN)2]   
 
A ± std = 83.67 ± 3.93 
B ± std = -0.360± 0.018 
C ± std = 1.0× 10-4 ± 7.6× 10-6 
R2 =  0.9982 
100 w1 100 w2 100 w1 100 w2 
46.29 3.65 31.33 6.90 
42.97 4.48 30.50 7.19 
41.10 4.93 29.15 7.70 
39.49 5.43 28.02 8.53 
33.48 7.22 26.67 8.71 
31.88 7.97 25.78 9.34 
31.04 8.23 24.65 9.82 
30.14 8.61 23.83 10.05 
29.56 8.74 23.44 10.23 
28.21 9.51 22.51 10.68 
27.42 9.64 22.06 10.81 
26.79 10.02 21.65 11.11 
25.73 10.32 21.33 11.30 
25.36 10.54 20.59 11.57 
25.07 10.57 20.29 11.73 
24.94 10.63 20.01 11.89 
24.54 10.79 19.53 12.27 
24.11 11.01 19.04 12.45 
23.72 11.19 18.79 12.54 
23.18 11.44 18.65 12.62 
22.14 12.02 18.34 12.86 
21.73 12.00 18.16 12.89 
21.37 12.21 18.03 12.95 
20.98 12.26 17.88 12.95 
20.60 12.44 17.57 13.17 
20.23 12.62 16.69 13.66 
19.98 12.68 16.50 13.76 
19.33 13.06 16.26 13.94 
19.12 13.06 16.14 13.95 
  15.91 14.01 
  15.62 14.28 
  15.39 14.44 
  15.11 14.45 
  14.79 14.76 
  14.58 14.86 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.2. - Phase diagrams of the IL/K3PO4-based based ABS composed of [C2mim]Cl (), 
[C2mim][CH3CO2] (), [N2,2,2,2]Br (), [C2mim][DMP] (), [C2mim][N(CN)2] (),  [C2mim][Tos] (+), 
[C2mim][CF3SO3] () + K3PO4 at (298 ± 1) K. Binodal curves adjusted using Equation 1 are represented 
in dashed lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.3 – Phase diagrams of different types of ABS: PEG 8000 (component 1) + NaPA 8000 
(component 2) + [C2mim]Cl as electrolyte (), [C2mim]Cl (component 1) + K3PO4 (component 2) (),  
PEG 1500 (component 1) + K3PO4 (component 2) + [C2mim]Cl as adjuvant1 (▲), PEG 1500 (component 
1) + [C2mim]Cl (component 2)2(). 
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